Page last updated: 2024-12-05

mexiletine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mexiletine is a class Ib antiarrhythmic drug that acts by blocking sodium channels, thereby reducing the rate of depolarization and decreasing the automaticity of heart cells. It is primarily used to treat ventricular arrhythmias, particularly those associated with premature ventricular contractions and ventricular tachycardia. Mexiletine is also sometimes used for the treatment of supraventricular arrhythmias, such as atrial fibrillation. The synthesis of mexiletine involves a multi-step process starting with 2,6-dimethylphenol and reacting it with various reagents to introduce the necessary functional groups. It is studied because of its potential to suppress arrhythmias in patients with cardiovascular diseases and is being explored for its potential applications in other conditions, such as pain management and neuroprotection. It is important to note that mexiletine can cause adverse effects, including nausea, vomiting, dizziness, and headache.'

Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4178
CHEMBL ID558
CHEBI ID6916
SCHEMBL ID16081
MeSH IDM0013719

Synonyms (112)

Synonym
BRD-A64092382-003-04-3
mexiletinum
(+-)-1-(2,6-dimethylphenoxy)propan-2-amine
mexiletina
gtpl2629
2-propanamine, 1-(2,6-dimethylphenoxy)-
ethylamine, 1-methyl-2-(2,6-xylyloxy)-
DIVK1C_000834
KBIO1_000834
SPECTRUM_001602
mexiletine [inn:ban]
mexiletinum [inn-latin]
mexiletina [inn-spanish]
brn 2092205
einecs 250-825-7
1-methyl-2-(2,6-xylyloxy)ethylamine
IDI1_000834
SPECTRUM5_001279
BSPBIO_002254
PRESTWICK3_000241
LOPAC0_000784
BPBIO1_000026
AB00053683
C07220
mexiletine
31828-71-4
DB00379
1-(2,6-dimethylphenoxy)-2-propanamine
(2rs)-1-(2,6-dimethylphenoxy)-2-aminopropane
1-(2',6'-dimethylphenoxy)-2-aminopropane
(+/-)-1-(2,6-dimethylphenoxy)propan-2-amine
1-methyl-2-(2,6-xylyloxy)ethanamine
PRESTWICK2_000241
KBIO2_007218
KBIO2_002082
KBIO3_001474
KBIOSS_002082
KBIOGR_001270
KBIO2_004650
SPBIO_002241
SPECTRUM3_000727
SPECTRUM4_000795
NINDS_000834
PRESTWICK1_000241
PRESTWICK0_000241
BSPBIO_000022
NCGC00162253-02
NCGC00162253-01
NCGC00015659-04
2-(2,6-dimethyl-phenoxy)-1-methyl-ethylamine(mexiletine)
bdbm50117271
2-(2,6-dimethyl-phenoxy)-1-methyl-ethylamine
1-(2,6-dimethylphenoxy)propan-2-amine
1-(2,6-dimethylphenoxy)-2-propanolamine
chebi:6916 ,
(rs)-mexiletine
CHEMBL558 ,
dl-mexiletine
D08215
mexiletine (inn)
FT-0658952
2-(2-aminopropoxy)-1,3-dimethylbenzene
EN300-54300
mexilitine
CCG-204869
NCGC00015659-11
NCGC00015659-10
NCGC00015659-05
NCGC00015659-07
NCGC00015659-02
NCGC00015659-09
NCGC00015659-03
NCGC00015659-08
1u511hhv4z ,
unii-1u511hhv4z
FT-0605484
AKOS015890265
2-amino-1-(2,6-dimethylphenoxy)propane
(+/-)-mexiletine
mexiletine [mi]
(2-((2,6-dimethylphenyl)oxy)-1-methylethyl)amine
mexiletine [who-dd]
(+/-)-2-amino-1-(2',6'-dimethylphenoxy)propane
mexiletine [vandf]
718619-78-4
mexiletine [inn]
2-(2,6-dimethylphenoxy)-1-methyl-ethylamine
2-(2,6-dimethylphenoxy)-1-methylethylamine
SCHEMBL16081
mexiletinehydrochloride
DTXSID8048446 ,
W-106874
1-(2,6-dimethylphenoxy)-2-aminopropane
mexitil (salt/mix)
mexiletine hydrochloride (salt/mix)
1-(2,6-dimethylphenoxy)-2-amino propane
AB00053683_10
AB00053683_11
1-(2,4-dimethylphenoxy)-2-propanamine
SBI-0050762.P003
Q420377
BRD-A64092382-003-09-2
mfcd00792471
SDCCGSBI-0050762.P004
NCGC00015659-23
NCGC00015659-13
SB45974
SB45976
dtxcid8028420
c01bb02
mexiletina (inn-spanish)
mexiletinum (inn-latin)

Research Excerpts

Overview

Mexiletine is an antiarrhythmic drug belonging to IB class, acting as sodium channel blocker. Mexiletine seems to be an option for the long-term treatment of recurrent VT/VF in adult patients with SHD, especially ICM, and ICD in whom CA was unsuccessful or not suitable.

ExcerptReferenceRelevance
"Mexiletine is a class 1b antiarrhythmic drug used for ventricular arrhythmias but is also found to be effective for paramyotonia congenita, potassium-aggravated myotonia, long QT-3 syndrome, and neuropathic pain. "( Mexiletine block of wild-type and inactivation-deficient human skeletal muscle hNav1.4 Na+ channels.
Russell, C; Wang, GK; Wang, SY, 2004
)
3.21
"Mexiletine is a very well-known class IB antiarrhythmic drug, whose enantiomers differ in both pharmacodynamic and pharmacokinetic properties, the (R)-isomer being the eutomer on experimental arrhythmias and in binding studies on cardiac voltage-gated sodium channels. "( Searching for new antiarrhythmic agents: evaluation of meta-hydroxymexiletine enantiomers.
Bruno, C; Budriesi, R; Carocci, A; Catalano, A; Cavalluzzi, MM; Defrenza, I; Di Mola, A; Franchini, C; Lentini, G; Micucci, M, 2013
)
2.07
"Mexiletine seems to be an option for the long-term treatment of recurrent VT/VF in adult patients with SHD, especially ICM, and ICD in whom CA was unsuccessful or not suitable."( Mexiletine for recurrent ventricular tachycardia in adult patients with structural heart disease and implantable cardioverter defibrillator: an EHRA systematic review.
Anic, A; Boveda, S; Conte, G; de Asmundis, C; Farkowski, MM; Karlinski, M; Lewandowski, M; Marijon, E; Mugnai, G; Providencia, R; Pytkowski, M, 2022
)
2.89
"Mexiletine is a class IB sodium-channel blocker. "( Indications for mexiletine in the new ESC guidelines and beyond.
Hohnloser, SH; Vamos, M; Zsigmond, EJ,
)
1.92
"Mexiletine is an antiarrhythmic drug belonging to IB class, acting as sodium channel blocker. "( Voltage-Gated Sodium Channel Blockers: Synthesis of Mexiletine Analogues and Homologues.
Carocci, A; Catalano, A; Franchini, C, 2021
)
2.31
"Mexiletine is a long-known drug used for the treatment of arrhythmias and repurposed in the 1980s for patients with nondystrophic myotonia (NDM). "( Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia.
de Visser, SJ; Hollak, CEM; Postema, PG; Stunnenberg, BC; Timmers, L; van den Berg, S; van der Ree, MH; van der Wel, V, 2021
)
2.35
"Mexiletine is a Class 1B antiarrhythmic drug that causes the disappearance of T-wave alternans by shortening QTc and peak-to-end of the T wave."( A case report: Is mexiletine usage effective in the shortening of QTC interval and improving the T-wave alternans in Timothy syndrome?
Ergul, Y; Tunca Sahin, G, 2018
)
1.54
"Mexiletine is a class Ib antiarrhythmic drug and is also used clinically to reduce or prevent myotonia. "( Mexiletine Block of Voltage-Gated Sodium Channels: Isoform- and State-Dependent Drug-Pore Interactions.
Munakata, T; Nakagawa, H; Sunami, A, 2019
)
3.4
"Mexiletine is an oral class IB antiarrhythmic agent. "( Antiarrhythmic Mexiletine: A Review on Synthetic Routes to Racemic and Homochiral Mexiletine and its Enantioseparation.
Carocci, A; Catalano, A, 2016
)
2.23
"Mexiletine is a similar but orally active anti-arrhythmic that has been demonstrated to be an effective analgesic in various types of neuropathic pain."( Mexiletine for refractory chronic daily headache: a report of nine cases.
Marmura, MJ; Passero, FC; Young, WB,
)
2.3
"Mexiletine is a class IB antiarrhythmic agent. "( Hemodialysis as an alternative treatment of mexiletine intoxication.
Akıncı, E; Coşkun, F; Yüzbaşıoglu, Y, 2011
)
2.07
"Mexiletine is a class I antiarrhythmic agent that is active after both oral and intravenous administration and similar in structure and activity to lidocaine. "( Pharmacology, electrophysiology, and pharmacokinetics of mexiletine.
Cerskus, I; Duff, HJ; Roden, D; Siddoway, L; Stone, W; Thompson, K; Wang, T; Woosley, RL, 1984
)
1.96
"Mexiletine is a useful antiarrhythmic agent for the treatment of ventricular arrhythmias. "( Oral mexiletine in the treatment of refractory ventricular arrhythmias: the role of electrophysiologic techniques.
Garan, H; McGovern, B; Ruskin, JN; Schoenfeld, MH; Whitford, E, 1984
)
2.22
"Mexiletine (MXT) is a drug endowed with a marked antiarrhythmic activity which may be included in 1B class of drugs employed in the therapy of arrhythmias. "( Possible adverse effects on the cardiovascular system of an antiarrhythmic drug mexiletine.
Bile, G; Giasi, M; Lamparelli, E; Marmo, E; Mazzeo, V; Rossi, F; Ruggiero, E; Scafuro, MA, 1984
)
1.94
"Mexiletine (Mexitil) is an effective antiarrhythmic drug for the treatment of ventricular dysrhythmias. "( Pharmacokinetics of mexiletine in renal insufficiency.
Baudinet, G; Carlier, J; de Landsheere, C; Dresse, A; El Allaf, D; Henrard, L; Quinaux, N, 1980
)
2.03
"As mexiletine is a potent cardiovascular drug and also as a measure of compliance, a rapid and sensitive gas-liquid chromatographic (GLC) method was developed to monitor its plasma concentration in patients who took part in the trial."( A modified gas-liquid chromatographic assay to monitor plasma mexiletine in a tinnitus study.
Chan, K; Pilling, M; Tse, J, 1982
)
1.02
"Mexiletine appears to be a promising alternative to lidocaine in the management of ventricular arrhythmias."( [Mexiletine in the treatment of lidocaine-resistant ventricular tachycardia. Preliminary results].
Chiariello, M; Clarizia, M; Condorelli, M; Santinelli, V; Stanislao, M; Turco, P, 1982
)
1.9
"Mexiletine is a group Ib antidysrhythmic agent with electrophysiologic effects similar to lidocaine."( Mexiletine overdose producing status epilepticus without cardiovascular abnormalities.
Hoffman, RS; Nelson, LS, 1994
)
2.45
"rac-Mexiletine is an orally effective class 1b antiarrhythmic agent used to treat ventricular arrhythmias. "( Stereoselective metabolism of rac-mexiletine by the fungus Cunninghamella echinulata yields the major human metabolites hydroxymethylmexiletine and p-hydroxymexiletine.
Coutts, RT; Foster, RT; Freitag, DG; Pasutto, FM; Pickard, MA, 1997
)
1.13
"Mexiletine is an antiarrhythmic agent used in the treatment of ventricular arrhythmia. "( Gas chromatographic-mass spectrometric determination of serum mexiletine concentration after derivatization with perfluorooctanoyl chloride, a new derivative.
Dasgupta, A; Yousef, O, 1998
)
1.98
"Mexiletine (Mexitil) is an antiarrhythmic agent used in the treatment of ventricular arrhythmia. "( Gas chromatography-electron ionization and chemical ionization mass spectrometric analysis of serum mexiletine concentration after derivatization with 2,2,2-trichloroethyl chloroformate: a novel derivative.
Appenzeller, P; Dasgupta, A; Moore, J, 1998
)
1.96
"Mexiletine is a substrate of CYP1A2. "( Involvement of CYP1A2 in mexiletine metabolism.
Kobayashi, K; Kuroiwa, Y; Nakajima, M; Shimada, N; Tokudome, S; Yamamoto, T, 1998
)
2.05
"Mexiletine is an orally active local anaesthetic agent which is structurally related to lidocaine (lignocaine) and has been used for alleviating neuropathic pain of various origins. "( Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.
Coukell, AJ; Jarvis, B, 1998
)
3.19
"Mexiletine is an alternative agent for the treatment of painful diabetic neuropathy in patients who have not had a satisfactory response to, or cannot tolerate, TCAs and/or other drugs."( Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.
Coukell, AJ; Jarvis, B, 1998
)
2.46
"Mexiletine is a class I antiarrhythmic drug with neuroprotective effects in models of brain ischemia attributable to inhibition of brain sodium channels. "( Differential interaction of R-mexiletine with the local anesthetic receptor site on brain and heart sodium channel alpha-subunits.
Catterall, WA; Qu, Y; Scheuer, T; Weiser, T, 1999
)
2.03
"Mexiletine is a class Ib antiarrhythmic drug used in the treatment of ventricular arrhythmias. "( Antioxidant action of the antiarrhythmic drug mexiletine in brain membranes.
Bavbek, M; Caner, H; Demirpençe, E; Kilinç, K, 1999
)
2
"Mexiletine is a class Ib drug that is widely used to treat ventricular arrhythmias. "( Systemic administration of mexiletine for attenuation of cerebral vasospasm following experimental subarachnoid haemorrhage.
Bavbek, M; Caner, H; Durieux, M; Kassell, NF; Kilinc, K; Kwan, AL; Lee, K, 2000
)
2.05
"Mexiletine is an oral sodium channel antagonist that has been reported to be effective in a variety of neuropathic pain syndromes. "( Efficacy of oral mexiletine for neuropathic pain with allodynia: a double-blind, placebo-controlled, crossover study.
Magnuson, S; Ridgeway, B; Wallace, MS,
)
1.91
"Mexiletine is a sodium channel blocker that has been used for the treatment of a variety of neuropathic pain syndromes. "( Effect of oral mexiletine on capsaicin-induced allodynia and hyperalgesia: a double-blind, placebo-controlled, crossover study.
Ando, K; Braun, J; Schulteis, G; Wallace, MS,
)
1.93
"Mexiletine is an antiarrhythmic drug that has been reported to exert antidystonic properties. "( Mexiletine in the treatment of torticollis and generalized dystonia.
Bernardini, S; Bonuccelli, U; Brotini, S; Gambaccini, G; Lucetti, C; Manca, ML; Nuti, A,
)
3.02
"Mexiletine is a frequently used antiarrhythmic drug in patients with an implantable cardioverter defibrillator, usually thought of as producing no or minimal effects on the defibrillation threshold."( Mexiletine related chronic defibrillation threshold elevation: case report and review of the literature.
Crystal, E; Ilia, R; Katz, A; Ovsyshcher, IE; Wagshal, AB, 2002
)
2.48
"Mexiletine is a new local anaesthetic antiarrhythmic agent whose chemical structure and electrophysiological properties closely resemble those of lignocaine although its anticonvulsant and pharmacokinetic properties differ from that drug. "( Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias.
Chew, CY; Collett, J; Singh, BN, 1979
)
3.15
"Mexiletine appears to be an effective alternative to currently available antiarrhythmic agents."( Mexiletine in treatment of ventricular arrhythmias. A long-term follow-up.
Hanson, A; Johansson, BW; Stavenow, L, 1979
)
2.42
"Mexiletine proved to be a safe therapy with negligible side effects at the medium dose range, even less than placebo; and remarkably, no cardiovascular side effects were noted."( Mexiletine in the treatment of diabetic neuropathy.
Federlin, K; Meyer, UE; Schumacher, HE; Stracke, H, 1992
)
2.45
"Mexiletine is a lidocaine analogue used in the treatment of symptomatic ventricular arrhythmias. "( Mexiletine-associated left ventricular dysfunction: a case study.
Ballas, SL; Baughman, KL; Griffith, LS; Veltri, EP, 1991
)
3.17
"Mexiletine is a Class IB antiarrhythmic which has basic and clinical electrophysiologic properties similar to lidocaine. "( Mexiletine: pharmacology and therapeutic use.
Cameron, J; Deering, TF; Estes, NA; Manolis, AS, 1990
)
3.16
"Mexiletine is a type I antiarrhythmic drug that is structurally similar to lidocaine. "( Mexiletine: a new type I antiarrhythmic agent.
Bauman, JL; Schrader, BJ, 1986
)
3.16
"Mexiletine is an antiarrhythmic agent, structurally similar to lidocaine, but useful orally as well as intravenously. "( Comparative study of mexiletine and quinidine in the treatment of ventricular ectopia.
Assey, ME; Hanger, KH; Hudson, WM; Miller, SC, 1985
)
2.03
"Mexiletine is a type 1B antiarrhythmic drug similar to lidocaine. "( Prolongation of ventricular depolarization. ECG manifestation of mexiletine toxicity.
Chandrasekaran, K; Hammill, SC; Nora, MO; Reeder, GS, 1989
)
1.96
"Mexiletine is an antiarrhythmic agent with structural and electrophysiologic properties similar to those of lidocaine. "( Pharmacology and clinical use of mexiletine.
Comess, KA; Fenster, PE,
)
1.86
"Mexiletine is a new class I antiarrhythmic agent similar to lidocaine which when used orally may have significant gastric side effects."( Usefulness and safety of cimetidine in patients receiving mexiletine for ventricular arrhythmia.
Klein, AL; Sami, MH, 1985
)
1.23
"Mexiletine is an investigational antiarrhythmic drug eliminated primarily by hepatic metabolism. "( Pharmacokinetics and nondialyzability of mexiletine in renal failure.
Stone, WJ; Wang, T; Woosley, RL; Wuellner, D, 1985
)
1.98

Effects

Mexiletine has a normalizing effect on the pathological gating properties of the L858F gain-of-function mutation in NaV 1.7. It has a liner range over the concentration range from 0.100-6.400 mg.

Mexiletine has a liner range over the concentration range from 0.100-6.400 mg. It has limited efficacy in the treatment of recurrent VT despite high-dose amiodarone therapy, in patients with ischemic heart disease.

ExcerptReferenceRelevance
"Mexiletine has a normalizing effect on the pathological gating properties of the L858F gain-of-function mutation in NaV 1.7, which, in part, might explain the beneficial effects of systemic treatment with mexiletine in patients with gain-of-function sodium channel disorders."( Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels.
Bennett, DL; Cox, JJ; Cregg, R; Werdehausen, R; Wood, JN, 2014
)
3.29
"Mexiletine has a liner range over the concentration range from 0.100-6.400 mg.L-1. "( [HPLC-fluorescent spectrometric determination of serum mexiletine concentration after derivatization with fluram].
Hong, YC; Jia, JY; Liu, GY; Xu, XR; Yu, C; Zhang, H, 2003
)
2.01
"Mexiletine has a little first pass hepatic metabolism and a large volume of distribution along with a high lipid solubility, and prolonged central nervous system toxicity may be expected."( Mexiletine overdose producing status epilepticus without cardiovascular abnormalities.
Hoffman, RS; Nelson, LS, 1994
)
2.45
"Mexiletine has a large and variable volume of distribution and an elimination half-life ranging from 6 to 12 hours."( Mexiletine: a new type I antiarrhythmic agent.
Bauman, JL; Schrader, BJ, 1986
)
2.44
"Mexiletine has limited efficacy in the treatment of recurrent VT despite high-dose amiodarone therapy, in patients with ischemic heart disease. "( Mexiletine or catheter ablation after amiodarone failure in the VANISH trial.
Deyell, MW; Doucette, S; Essebag, V; Gardner, M; Gray, C; Healey, JS; Hruczkowski, T; Leong-Sit, P; Nault, I; Nery, PB; Parkash, R; Rivard, L; Sapp, JL; Steinberg, C; Sterns, LD, 2018
)
3.37
"Mexiletine has been suggested as a cause of false-positive amphetamine results, but never confirmed as the causative agent in previous reports."( False-positive amphetamine results on several drug screening platforms due to mexiletine.
Harnish, TL; Jannetto, PJ; Kaleta, EJ; Langman, LJ; Linkenmeyer, JJ; Snozek, CLH; Stephen, J, 2018
)
1.43
"Mexiletine has a normalizing effect on the pathological gating properties of the L858F gain-of-function mutation in NaV 1.7, which, in part, might explain the beneficial effects of systemic treatment with mexiletine in patients with gain-of-function sodium channel disorders."( Mexiletine as a treatment for primary erythromelalgia: normalization of biophysical properties of mutant L858F NaV 1.7 sodium channels.
Bennett, DL; Cox, JJ; Cregg, R; Werdehausen, R; Wood, JN, 2014
)
3.29
"Four mexiletine analogues have been tested for their antiarrhythmic, inotropic, and chronotropic effects on isolated guinea pig heart tissues and to assess calcium antagonist activity, in comparison with the parent compound mexiletine. "( Synthesis, antiarrhythmic activity, and toxicological evaluation of mexiletine analogues.
Bruno, C; Budriesi, R; Carocci, A; Catalano, A; Cavalluzzi, MM; Chiarini, A; Colabufo, NA; Contino, M; De Palma, A; Di Cesare Mannelli, L; Franchini, C; Ghelardini, C; Habtemariam, S; Lentini, G; Lovece, A; Micucci, M; Perrone, MG; Roselli, M; Toma, M, 2016
)
1.18
"Mexiletine has a liner range over the concentration range from 0.100-6.400 mg.L-1. "( [HPLC-fluorescent spectrometric determination of serum mexiletine concentration after derivatization with fluram].
Hong, YC; Jia, JY; Liu, GY; Xu, XR; Yu, C; Zhang, H, 2003
)
2.01
"Mexiletine (Mex) has been proposed as a gene-specific therapy for patients with long-QT syndrome type 3 (LQT3) caused by mutations in the cardiac sodium channel gene (SCN5A). "( Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients.
Bloise, R; Liu, N; Napolitano, C; Priori, SG; Ruan, Y, 2007
)
2.03
"Mexiletine also has induced significant reduction of QTc and significant increase of cardiac rate, whereas it did not affect significantly the PR interval and blood pressure."( [Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias].
Bonatti, V; Botti, G; Favaro, L; Finardi, A; Rolli, A, 1981
)
1.23
"Mexiletine, a drug which has membrane-stabilising activity, had no effect on heart rate or arterial pressure."( Investigation into mechanism of lack of reflex tachycardia in response to hypotensive action of indoramin in dogs.
Harron, DW; Kerr, MJ; Shanks, RG,
)
0.85
"Mexiletine has a little first pass hepatic metabolism and a large volume of distribution along with a high lipid solubility, and prolonged central nervous system toxicity may be expected."( Mexiletine overdose producing status epilepticus without cardiovascular abnormalities.
Hoffman, RS; Nelson, LS, 1994
)
2.45
"Mexiletine has been reported to be hydroxylated by cytochrome P450 2D6 (CYP2D6) in humans. "( Involvement of CYP1A2 in mexiletine metabolism.
Kobayashi, K; Kuroiwa, Y; Nakajima, M; Shimada, N; Tokudome, S; Yamamoto, T, 1998
)
2.05
"Mexiletine has been evaluated in several randomised, placebo-controlled trials in patients with painful diabetic neuropathy."( Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.
Coukell, AJ; Jarvis, B, 1998
)
2.46
"Mexiletine has beneficial effects on myotonia."( Effect of mexiletine on sea anemone toxin-induced non-inactivating sodium channels of rat skeletal muscle: a model of sodium channel myotonia.
Camerino, DC; De Luca, A; Desaphy, JF; Tortorella, V, 1999
)
1.43
"Mexiletine has minimal effects on human experimental pain. "( Effect of oral mexiletine on capsaicin-induced allodynia and hyperalgesia: a double-blind, placebo-controlled, crossover study.
Ando, K; Braun, J; Schulteis, G; Wallace, MS,
)
1.93
"Mexiletine has the advantage of less frequent administration and lower toxicity."( Comparison of procainamide and mexiletine in prevention of ventricular arrhythmias after acute myocardial infarction.
Campbell, RW; Dolder, MA; Julian, DG; Murray, A; Prescott, LF; Talbot, RG, 1975
)
1.26
"Mexiletine has the pharmacodynamic and pharmacokinetic properties of an agent suitable for the chronic oral prophylaxis of serious ventricular arrhythmias in patients with ischaemic heart disease."( Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias.
Chew, CY; Collett, J; Singh, BN, 1979
)
2.42
"Mexiletine has considerable potential for causing neurologic, cardiac, or gastrointestinal side effects."( Mexiletine: a new type I antiarrhythmic agent.
Bauman, JL; Schrader, BJ, 1986
)
2.44

Actions

Mexiletine did not cause any significant changes in the normal AV conduction pathway. It tended to increase DFT, and defibrillation eventually was unsuccessful in 3 of the 9 dogs.

ExcerptReferenceRelevance
"mexiletine did not cause any significant changes in the normal AV conduction pathway; 2."( [Effects of mexiletine in the Wolff-Parkinson-White syndrome].
Atallah, G; Gressard, A; Kirkorian, G; Touboul, P, 1981
)
1.36
"Mexiletine tended to increase DFT [from 4.6 +/- 1.2 to 6.1 +/- 2.0 J (1.8 +/- 0.6 micrograms/ml); p < 0.05], and defibrillation eventually was unsuccessful in 3 of the 9 dogs."( Prolongation of intraventricular conduction time associated with fatal [correction of fetal] impairment of defibrillation efficiency during treatment with class I antiarrhythmic agents.
Ajiki, K; Inoue, H; Kuo, TT; Murakawa, Y; Nakajima, T; Oikawa, N; Sezaki, K; Sugimoto, T; Usui, M; Yamashita, T, 1995
)
1.01
"mexiletine inhibit the abnormal responses to low-threshold (A-fiber) afferent input in the strychnine model of allodynia (i.e., in the absence of peripheral or central nerve injury) at doses which affect normal nociception; and (iii) in the presence of i.t."( Comparable dose-dependent inhibition of AP-7 sensitive strychnine-induced allodynia and paw pinch-induced nociception by mexiletine in the rat.
Hodge, E; Khandwala, H; Loomis, CW, 1997
)
1.23
"Mexiletine was found to produce a statistically significant reduction in reported pain when compared to baseline or placebo."( The use of oral mexiletine for the treatment of pain after peripheral nerve injury.
Britell, CW; Chabal, C; Chaney, E; Jacobson, L; Mariano, A, 1992
)
1.35
"Mexiletine failed to produce any additional APD shortening beyond that produced by the introduction of tetrodotoxin (2.5 X 10(-6) M)."( The effects of mexiletine on action potential duration and its restitution in guinea pig ventricular muscles.
Atarashi, H; Kishida, H; Matsuo, S; Munakata, K, 1985
)
1.34

Treatment

Mexiletine treatment had no significant effect on the down-regulation of either gene. Mexiletine pre-treatment reduced hippocampal damage by approximately half when compared to control animals receiving saline alone.

ExcerptReferenceRelevance
"Mexiletine treatment started at 200 mg/day and was up-titrated by 200 mg increment each three days to reach a maximum dose of 600 mg/day for total treatment duration of 18 days for each cross-over period."( Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study.
Behin, A; Bouhour, F; Fontaine, B; Fournier, E; Franques, J; Hézode, M; Lacomblez, L; Magot, A; Nadaj-Pakleza, A; Payan, C; Péréon, Y; Sacconi, S; Vicart, S; Zahr, N, 2021
)
1.65
"Mexiletine treatment resulted in large dose-dependent reductions in muscle cramp frequency and severity."( A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.
Atassi, N; Barohn, RJ; Brown, RH; Cudkowicz, ME; Distad, JB; Graves, M; Greenblatt, DJ; Knox, AS; Macklin, EA; Parziale, N; Pestronk, A; Quinn, C; Salameh, JS; Shefner, JM; Simmons, Z; Swenson, A; Trivedi, J; Weiss, MD, 2016
)
1.47
"Mexiletine treatment, on the other hand, had no significant effect on the down-regulation of either gene."( The sodium channel blocker RS100642 reverses down-regulation of the sodium channel alpha-subunit Na(v) 1.1 expression caused by transient ischemic brain injury in rats.
Berti, R; Cunningham, BS; Dave, JR; Lu, XC; Price, RA; Tortella, FC; Williams, AJ; Yao, C, 2003
)
1.04
"Mexiletine treatment improved early behavioral recovery after SCI."( Mexiletine treatment-induced inhibition of caspase-3 activation and improvement of behavioral recovery after spinal cord injury.
Caner, H; Kaptanoglu, E; Kilinc, K; Solaroglu, I, 2005
)
2.49
"Mexiletine treatment did not affect these inhibitory responses."( Effects of mexiletine on electrical field stimulation-induced contractile responses in the ipsilateral and contralateral vasa deferentia after unilateral testicular torsion/detorsion.
Barun, S; Ercan, ZS; Moralioğlu, S; Ozen, IO; Sarioğlu, Y; Vural, IM, 2006
)
1.45
"Mexiletine treatment prevented the increase in lipid peroxidation and cerebral vasospasm."( The effect of mexiletine on the level of lipid peroxidation and apoptosis of endothelium following experimental subarachnoid hemorrhage.
Altinors, N; Atalay, B; Aydin, MV; Bavbek, M; Caner, H; Ozen, O; Sen, O, 2006
)
1.42
"In Mexiletine treated group the following results have been obtained: 19 excellent (76%), 4 good (16%) and 2 ineffective (8%)."( [Comparative study of the anti-arrhythmic activity of mexiletine and lidocaine in ventricular hyperkinetic arrhythmias].
Bonatti, V; Botti, G; Favaro, L; Finardi, A; Rolli, A, 1981
)
1.03
"Mexiletine pretreatment completely prevented histamine-induced airway constriction, with an airway area that was 94 +/- 4% of the control value during the histamine infusion (p = 0.07 compared with baseline)."( Prevention of bronchoconstriction by an orally active local anesthetic.
Brown, RH; Hirshman, C; Robbins, W; Staats, P, 1995
)
1.01
"Mexiletine pre-treatment reduced hippocampal damage by approximately half when compared to control animals receiving saline alone (45 vs."( The use-dependent sodium channel blocker mexiletine is neuroprotective against global ischemic injury.
Hewitt, KE; Lesiuk, HJ; Stys, PK, 2001
)
1.3
"The mexiletine treated group showed a significant reduction (p less than 0.05) in certain forms of ventricular dysrhythmias."( Prophylactic use of mexiletine in the elderly with acute myocardial infarction.
Datta-Chaudhari, ML; O'Brien, TD, 1990
)
1.08
"Mexiletine treatment resulted in a highly significant reduction in the mean number of premature ventricular beats from 163 to 28 and 30/24 h, respectively (p less than 0.01)."( The effects of mexiletine on cardiac arrhythmias in patients with cor pulmonale.
Górecka, D; Skwarski, K; Sliwiński, P; Zieliński, J, 1989
)
1.35
"Mexiletine treatment had no effect on tendon reflexes, vibration threshold levels, beat-to-beat variation in heart rate during deep breathing, and postural blood pressure response."( Mexiletine for treatment of chronic painful diabetic neuropathy.
Dejgard, A; Kastrup, J; Petersen, P,
)
2.3
"Treatment with mexiletine significantly reduced the number of electrical storm events (14 episodes vs."( Efficacy and tolerability of mexiletine treatment in patients with recurrent ventricular tachyarrhythmias and implantable cardioverter-defibrillator shocks.
Ateńska-Pawłowska, J; Kowalik, I; Lewandowski, M; Maciąg, A; Pytkowski, M; Sobiech, M; Sterliński, M; Syska, P; Szwed, H; Zając, D, 2017
)
1.09
"Treatment with mexiletine reduced the number and severity of pain episodes."( Mexiletine-responsive erythromelalgia due to a new Na(v)1.7 mutation showing use-dependent current fall-off.
Choi, JS; Dib-Hajj, SD; Han, C; Lin, Z; Tyrrell, L; Wang, X; Waxman, SG; Yang, Y; Zhang, L, 2009
)
2.14
"Treatment with mexiletine at either dosage was not associated with any serious adverse events, or with prolongation of the PR or QTc intervals or of QRS duration."( Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.
Annis, CL; Barbieri, CA; Dilek, N; Logigian, EL; Martens, WB; McDermott, MP; Moxley, RT; Pearson, AT; Thornton, CA; Wiegner, AW, 2010
)
2.14
"Rats treated with mexiletine, EGb 761, and mexiletine plus EGb 761 had significantly lower MDA levels than the control group (P<0.01)."( Effects of mexiletine, ginkgo biloba extract (EGb 761), and their combination on experimental head injury.
Akdemir, H; Koç, RK; Menkü, A; Narin, F; Saraymen, R; Tayfur, V, 2003
)
1.03
"pretreatment with mexiletine produced dose-dependent inhibition of fenvalerate-induced hyperalgesia and allodynia in mice, especially diabetic mice."( Effect of mexiletine on fenvalerate-induced nociceptive response in diabetic mice.
Kamei, J; Saitoh, A; Tamura, N, 2004
)
1.05
"Pretreatment with mexiletine, at doses of 3, 10 and 30 mg/kg, i.p., dose-dependently increased the tail-flick latency in vincristine-treated mice."( Effect of mexiletine on vincristine-induced painful neuropathy in mice.
Kamei, J; Nozaki, C; Saitoh, A, 2006
)
1.06
"Treatment with mexiletine led to resolution of the abnormalities exhibited during a short exercise test and repetitive stimulation following ice bath immersion."( Paramyotonia congenita: abnormal short exercise test, and improvement after mexiletine therapy.
Barohn, RJ; Jackson, CE; Ptacek, LJ, 1994
)
0.86
"Pretreatment with mexiletine (5-30 mg/kg i.v."( Comparable dose-dependent inhibition of AP-7 sensitive strychnine-induced allodynia and paw pinch-induced nociception by mexiletine in the rat.
Hodge, E; Khandwala, H; Loomis, CW, 1997
)
0.83
"Pretreatment with mexiletine resulted in a significant and dose-dependent inhibition of the nociceptive response produced by intrathecal (i.t.) injection of substance P (0.1 nM), somatostatin (1.0 nM), bradykinin (1 microgram/mouse) and prostaglandin (PG) F2 alpha (1 microgram/mouse)."( Effects of mexiletine on algogenic mediator-induced nociceptive responses in mice.
Hitosugi, H; Kamei, J; Kashiwazaki, T; Ohsawa, M,
)
0.84
"Pretreatment with mexiletine was associated with a significantly greater fall in serum potassium during adrenaline infusion, and pretreatment with flecainide with a greater fall in serum magnesium, as compared with placebo pretreatment Flecainide also caused a significant prolongation of the QRS duration before adrenalin infusion, and after all the active pretreatments a prolongation of QRS duration was seen during adrenaline infusion."( Metabolic, hemodynamic, and electrocardiographic responses to increased circulating adrenaline: effects of pretreatment with class 1 antiarrhythmics.
Gullberg, B; Hansen, O; Johansson, BW, 1991
)
0.6
"Treatment with mexiletine (oral in 13 and intravenous in 1) was begun and electrophysiologic testing was repeated."( Role of combination drug therapy with a class IC antiarrhythmic agent and mexiletine for ventricular tachycardia.
Franklin, S; Fuchs, T; Mendes, L; Podrid, PJ, 1991
)
0.85

Toxicity

Mexiletine was safe at both doses and well-tolerated at 300 mg/d. Adverse effects at 900 mg/D led to a high rate of discontinuation. No significant correlation was found between plasma concentration of mexiletine and the therapeutic effect.

ExcerptReferenceRelevance
" Tolerable adverse effects were relatively common but transient and dose related."( Mexiletine. Long-term efficacy and side effects in patients with chronic drug-resistant potentially lethal ventricular arrhythmias.
Aragon, E; Faitel, K; Frumin, H; Kerin, NZ; Marinescu, G; Rubenfire, M, 1990
)
1.72
" A common cause of drug trial failure for both drugs was the occurrence of adverse effects that frequently appeared well after hospital discharge."( Mexiletine and tocainide: a comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testing.
Barbey, JT; Echt, DS; Kopelman, HA; Murray, KT; Roden, DM; Siddoway, LA; Woosley, RL, 1989
)
1.72
" There was no difference in the incidence of adverse reactions between the 2 groups; in both, the most common side effects were related to the gastrointestinal and central nervous systems."( Comparative efficacy and safety of oral mexiletine and quinidine in benign or potentially lethal ventricular arrhythmias.
Morganroth, J, 1987
)
0.54
" Since some patients with peptic ulcer disease or gastric hyperacidity on mexiletine may benefit from the addition of cimetidine, it was important to rule out any significant adverse interaction between the two drugs in such patients."( Usefulness and safety of cimetidine in patients receiving mexiletine for ventricular arrhythmia.
Klein, AL; Sami, MH, 1985
)
0.74
" In all instances adverse effects emerged before ectopic activity was suppressed satisfactorily prohibiting further increment of dosage."( Increased incidence of side effects after encainide: a newly developed antiarrhythmic drug.
Berchtold-Kanz, E; Hust, M; Just, H; Nitsche, K; Schwarz, G, 1984
)
0.27
" The comparison of hemodynamic, electrocardiographic and toxic effects of mexiletine with those produced by other antiarrhythmics showed that mexiletine placed itself among the better tolerated antiarrhythmics during the administration of progressively increasing doses."( Hemodynamic, electrocardiographic and toxic effects of the intravenous administration of increasing doses of mexiletine in the dog. Comparison with similar effects produced by other antiarrhythmics.
Carlier, J, 1980
)
0.7
" These findings suggest that the serum toxic level of lidocaine in children is different from that in adults, and that careful observation and appropriate management for the children with lidocaine therapy should be necessary, even though the serum level of lidocaine ranges within the therapeutic level."( [Efficacy and side effects of lidocaine by intravenous drip infusion in children with intractable seizures].
Aihara, M; Hatakeyama, K; Hinohara, Y; Kamiya, Y; Kanemura, H; Nakazawa, S; Sata, Y; Shimoda, C, 1997
)
0.3
" No significant correlation was found between plasma concentration of mexiletine and the therapeutic effect or adverse events."( Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group.
Lins, PE; Ljunggren, JG; Oskarsson, P, 1997
)
0.84
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Adverse events amounted 20% in the riluzole and 33% in the mexiletine groups."( A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: Efficacy and safety of sodium channel blocker phase II trial.
Beppu, M; Fujimaki, Y; Hanaoka, H; Iwai, Y; Kimura, H; Kuwabara, S; Misawa, S; Mitsuma, S; Mizuno, T; Nakagawa, M; Noto, Y; Sato, Y; Sawaguchi, K; Sekiguchi, Y; Shibuya, K; Shimizu, T; Tsuji, Y; Watanabe, K, 2015
)
0.91
"The only serious adverse event among active arm participants was one episode of imbalance."( A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.
Atassi, N; Barohn, RJ; Brown, RH; Cudkowicz, ME; Distad, JB; Graves, M; Greenblatt, DJ; Knox, AS; Macklin, EA; Parziale, N; Pestronk, A; Quinn, C; Salameh, JS; Shefner, JM; Simmons, Z; Swenson, A; Trivedi, J; Weiss, MD, 2016
)
0.75
"Mexiletine was safe at both doses and well-tolerated at 300 mg/d but adverse effects at 900 mg/d led to a high rate of discontinuation."( A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.
Atassi, N; Barohn, RJ; Brown, RH; Cudkowicz, ME; Distad, JB; Graves, M; Greenblatt, DJ; Knox, AS; Macklin, EA; Parziale, N; Pestronk, A; Quinn, C; Salameh, JS; Shefner, JM; Simmons, Z; Swenson, A; Trivedi, J; Weiss, MD, 2016
)
2.19
"This study provides Class I evidence that mexiletine is safe when given daily to patients with amyotrophic lateral sclerosis at 300 and 900 mg and well-tolerated at the lower dose."( A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression.
Atassi, N; Barohn, RJ; Brown, RH; Cudkowicz, ME; Distad, JB; Graves, M; Greenblatt, DJ; Knox, AS; Macklin, EA; Parziale, N; Pestronk, A; Quinn, C; Salameh, JS; Shefner, JM; Simmons, Z; Swenson, A; Trivedi, J; Weiss, MD, 2016
)
1.01
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" No clinically significant adverse events were reported."( Efficacy and safety of mexiletine in non-dystrophic myotonias: A randomised, double-blind, placebo-controlled, cross-over study.
Behin, A; Bouhour, F; Fontaine, B; Fournier, E; Franques, J; Hézode, M; Lacomblez, L; Magot, A; Nadaj-Pakleza, A; Payan, C; Péréon, Y; Sacconi, S; Vicart, S; Zahr, N, 2021
)
0.93
" As for adverse events, gastrointestinal complaints were most frequently observed (33% of the patients)."( Effectiveness and safety of mexiletine in patients at risk for (recurrent) ventricular arrhythmias: a systematic review.
Hollak, CEM; Jacobs, BAW; Postema, PG; Rosenberg, N; Stolwijk, N; van den Berg, S; van der Ree, MH; van der Wel, V; van Dussen, L; Wilde, AAM, 2022
)
1.02

Pharmacokinetics

Our objective was to study the potential pharmacokinetic and electrophysiological interactions between mexiletine and propafenone. The bioavailability and most important pharmacokinetics were to be determined in comparison to a commercial reference preparation registered according to the AMG 1976.

ExcerptReferenceRelevance
" However, the pharmacokinetic interaction between mexiletine and theophylline has not been clarified."( [The effect of mexiletine on theophylline pharmacokinetics in patients with bronchial asthma].
Hariya, Y; Hayakawa, H; Inafuku, M; Nagasawa, K; Nakahara, Y; Ohtsu, F; Suzuki, T; Yoshioka, Y, 1992
)
0.89
" We conducted a two-way crossover study in 15 healthy male subjects to assess the magnitude of the pharmacokinetic interaction between mexiletine and theophylline."( Influence of mexiletine on the pharmacokinetics of theophylline in healthy volunteers.
Destache, CJ; Hilleman, DE; Mohiuddin, SM; Nipper, HC; Stoysich, AM, 1991
)
0.85
" There were no significant differences in elimination half-life (t1/2) and mean residence time (MRT) for mexiletine and its metabolites."( Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects.
Filipek, M; Koliński, P; Paczkowski, D; Sadowski, Z,
)
0.67
" The mean values for elimination half-life and oral clearance were 12."( Pharmacokinetics of mexiletine in the elderly.
Barbeau, G; Blouin, M; Fiset, C; Grech-Bélanger, O; Kishka, P; LeBoeuf, E, 1989
)
0.6
" The terminal elimination half-life of S(+)mexiletine was 11."( The pharmacokinetics of the enantiomers of mexiletine in humans.
Igwemezie, L; Kerr, CR; McErlane, KM, 1989
)
0.8
"We investigated the influence of bias in the estimates of the population pharmacokinetic parameters on the performance of Bayesian feedback in achieving a desired drug serum concentration."( Estimates of the population pharmacokinetic parameters and performance of Bayesian feedback: a sensitivity analysis.
Steiner, C; Vozeh, S, 1987
)
0.27
" The method deals with individual linear compartmental mammillary pharmacokinetic models and requires estimated values of model parameters."( Steady-state dosage regimen calculations in linear pharmacokinetics.
Bruno, R; Cano, JP; Iliadis, A, 1986
)
0.27
" No differences in the pharmacokinetic parameters of mexiletine related to age were observed."( Effects of age on the pharmacokinetics of mexiletine.
Carlier, J; Dressé, A; el Allaf, D, 1986
)
0.78
" In the same subjects the sensitivity of PEP to minor negative inotropic effects of mexiletine and disopyramide measured at Cmax was confirmed."( Uncorrected pre-ejection period: a simple non-invasive measurement for pharmacodynamic screening of inotropic activity.
Boissel, JP; Galleyrand, J; Rousson, D; Silie, M, 1987
)
0.5
" The decline of MEX in plasma was three-exponential, with a terminal half-life of 14."( Pharmacokinetics of intravenous mexiletine in patients with acute myocardial infarction.
Halinen, MO; Helin, MJ; Pentikäinen, PJ,
)
0.41
" Elimination half-life is 9 to 11 hours after intravenous or oral administration."( Pharmacology, electrophysiology, and pharmacokinetics of mexiletine.
Cerskus, I; Duff, HJ; Roden, D; Siddoway, L; Stone, W; Thompson, K; Wang, T; Woosley, RL, 1984
)
0.51
"This article reviews clinical pharmacokinetic data on 8 new antiarrhythmic agents."( Clinical pharmacokinetics of the newer antiarrhythmic agents.
Gillis, AM; Kates, RE,
)
0.13
" The elimination half-life was 15."( Pharmacokinetics of oral mexiletine in patients with acute myocardial infarction.
Halinen, MO; Helin, MJ; Pentikäinen, PJ, 1983
)
0.57
"Although pharmacodynamic factors are very important in regard to the need for dose adaptation of mexiletine, pharmacokinetic factors also play a role."( Adaptation of the dose of mexiletine according to pharmacokinetic data.
Bogaert, M, 1980
)
0.78
"A new data analysis approach, NON-MEM, proposed by Sheiner and Beal, has been employed to estimate the population pharmacokinetic parameters of oral mexiletine in patients treated for arrhythmias."( Population pharmacokinetic parameters in patients treated with oral mexiletine.
Follath, F; Katz, G; Steiner, V; Vozeh, S, 1982
)
0.7
"In the course of this study, both the bioavailability and the most important pharmacokinetic parameters of a newly development mexiletine (CAS 31828-71-4) preparation (Mexiletine-ratiopharm mite, dosage 200 mg of mexiletine) were to be determined in comparison to a commercial reference preparation registered according to the AMG 1976, after single oral administration."( [The pharmacokinetics and bioavailability of a new mexiletine preparation in healthy volunteers].
Hutt, V; Jaeger, H; Kappler, J; Pabst, G; Salama, Z, 1995
)
0.75
" The calculated CLH values were then compared to literature values of clearance (CL) to the same metabolite obtained during pharmacokinetic studies in humans."( Predicting the hepatic clearance of xenobiotics in humans from in vitro data.
Hoener, BA, 1994
)
0.29
" In this respect, slow EM individuals generally presented intermediate values of those pharmacokinetic parameters."( Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.
Abrams, SM; Johnston, A; Lledó, P; Patel, M; Pearson, RM; Turner, P, 1993
)
0.51
" The final pharmacokinetic parameters are, CL/F=0."( Population pharmacokinetic analysis of mexiletine in adult arrhythmic patients in Japanese population.
Iwai, T; Koue, T; Shibakawa, M; Uenaka, K; Ueno, K, 1998
)
0.57
"Enzymatic hydrolysis with beta-glucuronidase/sulfatase was used for the enantioselective determination of N-hydroxymexiletine glucuronide in plasma for pharmacokinetic studies."( Enantioselective analysis of N-hydroxymexiletine glucuronide in human plasma for pharmacokinetic studies.
Cesarino, EJ; Dreossi, SA; Lanchote, VL; Mere Júnior, Y; Santos, SR; Santos, VJ, 1999
)
0.78
" Mexiletine is eliminated slowly in humans (with an elimination half-life of 10 hours)."( Clinical pharmacokinetics of mexiletine.
Labbé, L; Turgeon, J, 1999
)
1.5
" Our objective was to study the potential pharmacokinetic and electrophysiological interactions between mexiletine and propafenone."( Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
Adedoyin, A; Champagne, J; Gilbert, M; Hamelin, B; Labbé, L; Lefebvre, M; Lessard, E; O'Hara, G; Turgeon, J, 2000
)
0.77
" Pharmacokinetic parameters of propafenone were not changed during concomitant administration of mexiletine in subjects of either phenotype."( Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
Adedoyin, A; Champagne, J; Gilbert, M; Hamelin, B; Labbé, L; Lefebvre, M; Lessard, E; O'Hara, G; Turgeon, J, 2000
)
0.77
" Our objective was to study the potential pharmacokinetic interaction between fluvoxamine and mexiletine."( Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men.
Fujimura, Y; Kusumoto, M; Mashimo, K; Nishihori, T; Oda, A; Takaya, K; Takeda, K; Tanaka, K; Ueno, K, 2001
)
0.78
"The area under the concentration-time curve and serum peak concentration of mexiletine in study 2 were significantly increased compared with those in study 1 (10."( Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men.
Fujimura, Y; Kusumoto, M; Mashimo, K; Nishihori, T; Oda, A; Takaya, K; Takeda, K; Tanaka, K; Ueno, K, 2001
)
0.79
"Our objective was to elucidate the mechanism of pharmacokinetic interaction between lidocaine and mexiletine, because an unexpected increase in plasma lidocaine concentration accompanied by severe side effects was observed when mexiletine was administered to a patient with dilated cardiomyopathy."( Possible mechanism for pharmacokinetic interaction between lidocaine and mexiletine.
Fukuzawa, M; Funakoshi, S; Kugaya, Y; Maeda, Y; Murakami, T; Nakamura, M; Takano, M; Tsukiai, S; Yamasaki, M, 2002
)
0.76
" This pharmacokinetic interaction was not attributable to a metabolic interaction as evaluated by plasma lidocaine metabolites concentrations."( Possible mechanism for pharmacokinetic interaction between lidocaine and mexiletine.
Fukuzawa, M; Funakoshi, S; Kugaya, Y; Maeda, Y; Murakami, T; Nakamura, M; Takano, M; Tsukiai, S; Yamasaki, M, 2002
)
0.55
" A comparison is also presented between several methods based on animal pharmacokinetic data, using the same set of proprietary compounds, and it lends further support for the use of this method, as opposed to methods that require the gathering of pharmacokinetic data in laboratory animals."( Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY, 2004
)
0.32
" This method was successfully applied to the analysis of the three drugs in rat plasma and their pharmacokinetic studies."( Pharmacokinetic study of three cardiovascular drugs by high-performance liquid chromatography using pre-column derivatization with 9,10-anthraquinone-2-sulfonyl chloride.
Cui, S; Feng, F; Liu, H; Ma, M; Xie, D; Xu, S, 2007
)
0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"5 ng x h/mL), and the half-life (1."( Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics.
Homma, M; Inomata, S; Kohda, Y; Momo, K; Osaka, Y; Tanaka, M, 2010
)
0.75
" The goal was to validate MVRC as a pharmacodynamic (PD) biomarker for drugs targeting muscle excitability."( Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double-blind placebo-controlled cross-over study.
de Kam, ML; Groeneveld, GJ; Heuberger, JAAC; Koopmans, IW; Ruijs, TQ; Tannemaat, MR, 2022
)
0.95

Compound-Compound Interactions

The efficacy of mexiletine used alone, and in combination with a class Ia antiarrhythmic drug, was assessed in 159 previously drug-refractory patients with ventricular tachycardia.

ExcerptReferenceRelevance
"Antiarrhythmic and electrophysiological effects of three class I antiarrhythmic agents, one from each subclass A, B, and C, were assessed in single use and in combination with amiodarone in patients with inducible, sustained ventricular tachycardia that was not suppressed by monotherapy with these agents."( A prospective comparison of class IA, B, and C antiarrhythmic agents in combination with amiodarone in patients with inducible, sustained ventricular tachycardia.
Kadish, A; Morady, F; Toivonen, L, 1991
)
0.28
"Class I antiarrhythmic agents slow ventricular conduction and increase ventricular refractoriness when used in combination with amiodarone."( A prospective comparison of class IA, B, and C antiarrhythmic agents in combination with amiodarone in patients with inducible, sustained ventricular tachycardia.
Kadish, A; Morady, F; Toivonen, L, 1991
)
0.28
"Using standard microelectrode techniques, the authors compared the effects of 15 to 125 microM concentrations of mexiletine, 31 to 500 microM concentrations of sotalol and 15 to 125 microM of mexiletine combined with 125 microM sotalol, on the beat-to-beat maximum rate of depolarization of phase 0 of the action potential (Vmax) of porcine papillary muscles and Purkinje fibres stimulated by 30 beat trains at a frequency of 1 Hz."( The cellular electropharmacology of mexiletine combined with sotalol in porcine papillary muscle and Purkinje fibre. I. Alteration of mexiletine-induced Vmax depression.
Ahmed, A; Berman, ND; Wang, LY, 1990
)
0.76
"Using standard microelectrode techniques, the authors compared the effects of 15 to 125 microM concentrations of mexiletine, 31 to 500 microM concentrations of sotalol and 15 to 125 microM of mexiletine combined with 125 microM sotalol, on the beat-to-beat action potential duration and refractoriness of porcine papillary muscles and Purkinje fibres stimulated by 30 beat trains at a frequency of 1 Hz."( The cellular electropharmacology of mexiletine combined with sotalol in porcine papillary muscle and Purkinje fibre. II. Effects on action potential duration and refractoriness.
Ahmed, A; Berman, ND; Wang, LY, 1990
)
0.76
"The efficacy of mexiletine used alone, and in combination with a class Ia antiarrhythmic drug, was assessed in 159 previously drug-refractory patients with ventricular tachycardia (VT) during serial electrophysiologic studies and during long-term (5-year) clinical follow-up."( Long-term efficacy of mexiletine alone and in combination with class Ia antiarrhythmic drugs for refractory ventricular arrhythmias.
Garan, H; McElroy, M; McGovern, B; Newell, JB; Ruskin, JN; Schoenfeld, MH; Whitford, EG, 1988
)
0.94
"The electrophysiologic effects and clinical efficacy of mexiletine used alone or in combination with class IA agents were studied in 35 patients with recurrent sustained ventricular tachycardia (VT) or ventricular fibrillation refractory to nonexperimental antiarrhythmic agents."( Electrophysiologic effects and clinical efficacy of mexiletine used alone or in combination with class IA agents for refractory recurrent ventricular tachycardias or ventricular fibrillation.
Felder, SD; Fisher, JD; Kim, SG; Waspe, LE, 1986
)
0.77

Bioavailability

Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration. The bioavailability of mexiletine given by this route is complete and the kinetics are linear with dose.

ExcerptReferenceRelevance
" Pharmacokinetic studies have shown that oral absorption is rapid with bioavailability of 80-90%."( Mexiletine: pharmacology and therapeutic use.
Cameron, J; Deering, TF; Estes, NA; Manolis, AS, 1990
)
1.72
"In 16 healthy males bioavailability of Mexicord (Polfa) was studied, in comparison with mexiletine of foreign made."( [Comparative evaluation of biological availability and anti-arrhythmia effectiveness of Mexicard (mexiletine Polfa)].
Filipek, M; Koliński, P; Markiewicz, M; Nartowicz, E; Paczkowski, D; Sadowski, Z, 1989
)
0.72
" The rate of absorption of the drug from the gastrointestinal tract was significantly slower in the elderly (1."( Pharmacokinetics of mexiletine in the elderly.
Barbeau, G; Blouin, M; Fiset, C; Grech-Bélanger, O; Kishka, P; LeBoeuf, E, 1989
)
0.6
" Uptake and distribution of mexiletine are rapid, systemic bioavailability is about 90%, and tissue distribution is extensive."( Pharmacology, electrophysiology, and pharmacokinetics of mexiletine.
Cerskus, I; Duff, HJ; Roden, D; Siddoway, L; Stone, W; Thompson, K; Wang, T; Woosley, RL, 1984
)
0.81
" Flecainide pharmacokinetics are suitable for oral use but encainide disposition is complex with variable bioavailability and active metabolites that contribute substantially to activity."( Clinical profiles of newer class I antiarrhythmic agents--tocainide, mexiletine, encainide, flecainide and lorcainide.
Pottage, A, 1983
)
0.5
" Lorcainide is also a class Ic antiarrhythmic drug, the bioavailability of which is nonlinear."( Clinical pharmacokinetics of the newer antiarrhythmic agents.
Gillis, AM; Kates, RE,
)
0.13
" When the drugs were taken on an empty stomach, activated charcoal given 5 min or 60 min afterwards reduced the bioavailability of the drugs by 75-98% or 10-60%, respectively."( Do gastric contents modify antidotal efficacy of oral activated charcoal?
Neuvonen, PJ; Olkkola, KT, 1984
)
0.27
" Mexiletine was well absorbed from the intestinal tract."( Pharmacokinetics and the antiarrhythmic effect of mexiletine in patients with chronic ventricular arrhythmias.
Ebihara, A; Hashimoto, T; Hosoda, S; Kondo, K; Ohashi, K; Oka, T, 1984
)
1.43
"The dissolution and bioavailability of two preparations of mexiletine hydrochloride (200 mg), one available commercially as Mexitil and one modified by the Hospital Pharmacy for a clinical trial, were investigated in a cross-over study with healthy volunteer subjects."( The dissolution and oral bioavailability of mexiletine capsules modified for clinical trial. A preliminary report.
Chan, K; Deeks, PA; Pilling, M; Tse, J, 1983
)
0.77
"6 mg), both separately and combined, on the absorption rate and relative oral bioavailability of the antiarrhythmic drug, mexiletinee (400 mg) was studied in eight fasting healthy males using a Latin Square design for order of pretreatment administration."( The effect of metoclopramide and atropine on the absorption of orally administered mexiletine.
Birkett, DJ; Grygiel, JJ; Meffin, PJ; Smith, KJ; Wing, LM, 1980
)
0.69
" The bioavailability of mexiletine given by this route is complete and the kinetics are linear with dose."( Plasma mexiletine concentrations following combined oral and intramuscular administration.
Bradbrook, ID; Feldschreiber, P; Morrison, PJ; Rogers, HJ; Spector, RG, 1981
)
1.02
"In the course of this study, both the bioavailability and the most important pharmacokinetic parameters of a newly development mexiletine (CAS 31828-71-4) preparation (Mexiletine-ratiopharm mite, dosage 200 mg of mexiletine) were to be determined in comparison to a commercial reference preparation registered according to the AMG 1976, after single oral administration."( [The pharmacokinetics and bioavailability of a new mexiletine preparation in healthy volunteers].
Hutt, V; Jaeger, H; Kappler, J; Pabst, G; Salama, Z, 1995
)
0.75
"Mexiletine, a class Ib antiarrhythmic agent, is rapidly and completely absorbed following oral administration with a bioavailability of about 90%."( Clinical pharmacokinetics of mexiletine.
Labbé, L; Turgeon, J, 1999
)
2.04
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Several compounds from this series displayed good oral bioavailability and exposure and were efficacious in a rat model of neuropathic pain."( Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain.
Abbadie, C; Dean, B; Duffy, JL; Felix, JP; Garcia, ML; Gonzalez, E; Hoyt, SB; Jochnowitz, N; Kaczorowski, GJ; Karanam, BV; Li, X; London, C; Lyons, KA; Macintyre, DE; Martin, WJ; McGowan, E; Ok, H; Parsons, WH; Priest, BT; Smith, MM; Tschirret-Guth, R; Warren, VA; Williams, BS, 2007
)
0.34
" Subsequent optimization led to 15, a potent, selective, and orally bioavailable inhibitor of uPA."( Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator.
Callaghan, O; Chessari, G; Congreve, M; Cowan, SR; Frederickson, M; Matthews, JE; McMenamin, R; Smith, DM; Vinković, M; Wallis, NG, 2008
)
0.64
", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule."( Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016
)
0.43

Dosage Studied

Consensus was achieved for the average long-term dosage of mexiletine (NaMuscla) in practice. We recommend a slightly reduced dosage of 400-600 mg mex toiletine/day (usually 600-800 mg) for patients with end-stage renal insufficiency.

ExcerptRelevanceReference
" Factors which influence urinary pH should be considered when the dosage of mexiletine is chosen."( The effect of spontaneous changes in urinary pH on mexiletine plasma concentrations and excretion during chronic administration to healthy volunteers.
Burgess, CD; Hamer, NA; Johnston, A; Wadsworth, J; Warrington, SJ, 1979
)
0.74
" In 26 of the 32 patients optimum dosage for maximum beneficial effect appeared to be 200 mg 3 times daily."( [Treatment of rhythm disorders of ventricular origin with KO 1173 (Mexiletin) (author's transl)].
Esser, H; Kikis, D, 1977
)
0.26
" The long therapeutic half-life of the drug allowed convenient dosage schedule and good compliance."( Mexiletine. Use in control of chronic drug-resistant ventricular arrhythmia.
Abinader, EG; Cooper, M, 1979
)
1.7
"A combined intravenous and oral dosage regime for mexiletine has been evaluated in volunteer subjects."( A schedule for combined intravenous and oral dosing with mexiletine.
Hampel, G; Holt, DW; Volans, GN, 1979
)
0.76
" Mexitil--a potent class I antiarrhythmic drug--significantly reduced the incidence of ventricular arrhythmias at rest, normal physical activity and after ergometric loading during initial intravenous therapy followed by continuous oral administration over a three-week period at a daily dosage of 600 to 800 mg."( [The influence of mexiletin on ventricular arrhythmias during ergometric exercise (author's transl)].
Pozenel, H, 1977
)
0.26
" Optimal dosage for this population appeared to be at least 800 mg/day."( A multiple-dose study of mexiletine (Kö 1173).
Brock, JT; Cereghino, JJ; Kupferberg, HJ; Penry, JK; Smith, LD; Van Meter, JC; White, BG, 1975
)
0.56
" During dosing (10 mg kg-1 twice a day for 10 days) no effects on the electrocardiogram, monitored in conscious animals, were observed despite modest reductions (15-18%) in the maximum rate of depolarization of papillary muscle excised 1 or 6 h after completion of the dosing regime."( Antiarrhythmic, electrophysiological and haemodynamic effects of prolonged oral dosing with Org 7797 in the anaesthetized rat.
Delbressine, L; Harris, N; Kane, KA; Muir, AW; Winslow, E, 1992
)
0.28
" With an increase in the antiarryhthmic dosage level, the efficacy does not rise proportionally."( Mexiletine in the treatment of diabetic neuropathy.
Federlin, K; Meyer, UE; Schumacher, HE; Stracke, H, 1992
)
1.73
"75 to 2 micrograms ml-1) in all patients after a twice daily dosage regimen."( Simultaneous modelling of mexiletine and hydroxy-methyl-mexiletine data after single- and multiple-dose administration of a sustained-release mexiletine formulation.
Bruno, R; Cano, JP; Djiane, P; Iliadis, A; Santoni, Y; Serradimigni, A, 1992
)
0.58
" In conclusion, although mexiletine may cause cardiodepressant effects in any patient with severe left ventricular dysfunction, dosing which results in a high (but still therapeutic) plasma level is more likely to cause haemodynamic deterioration."( Cardiodepressant effects of mexiletine in patients with severe left ventricular dysfunction.
Gottlieb, SS; Weinberg, M, 1992
)
0.88
"5 mg kg-1, 1 after 8 mg kg-1); two animals died after 1 and 8 mg kg-1, respectively; one remained unchanged even at the highest dosage (16 mg kg-1)."( Resolution and electrophysiological effects of mexiletine enantiomers.
Bélanger, PM; Grech-Bélanger, O; Harron, DW; Turgeon, J; Uprichard, AC, 1991
)
0.54
"The antiarrhythmic effectiveness and safety of 12-h oral administration of mexiletine were evaluated in adult outpatients with a baseline hourly rate of PVCs of 30 or higher who had initially shown at least a 50 percent reduction of this rate when treated with mexiletine at an 8-h dosage interval."( Efficacy of oral mexiletine therapy at a 12-h dosage interval.
Hughes, EM; MacGregor, TR; Sharon, G; Steen, SN, 1990
)
0.85
" In five out of those patients, we attempted combined therapy with a reduced dosage of those drugs that caused side effects."( Efficacy of disopyramide and mexiletine used alone or in combination in the treatment of ventricular premature beats.
Hiraoka, M; Motomiya, T; Sakurada, H, 1991
)
0.57
" Maximum tissue concentrations of the enantiomers were observed at 5 min after dosage in all tissues studied."( Tissue distribution of mexiletine enantiomers in rats.
Beatch, GN; Igwemezie, L; McErlane, KM; Walker, MJ, 1991
)
0.59
" Theophylline dosage adjustments will be required in patients who receive concomitant mexiletine therapy."( Influence of mexiletine on the pharmacokinetics of theophylline in healthy volunteers.
Destache, CJ; Hilleman, DE; Mohiuddin, SM; Nipper, HC; Stoysich, AM, 1991
)
0.87
" In the dosage range 600 to 900 mg daily mexiletine effectively suppresses premature ventricular contractions (PVCs) in 25% to 79% of patients, with or without underlying cardiac disease."( Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.
Brogden, RN; Monk, JP, 1990
)
1.99
" Dose-response curves were constructed for right ventricular effective refractory period, epicardial monophasic action potential duration, and conduction time (the time from pacing stimulus to the upstroke of the monophasic action potential signals) during constant rate pacing."( Electropharmacologic synergism with mexiletine and quinidine.
Duff, HJ; Kolodgie, FD; Roden, DM; Woosley, RL,
)
0.41
" With mexitil dosage of 400-600 mg orally per day there was a marked antiarrhythmic effect in 68% of patients."( [Clinical study of the effectiveness of mexitil in the treatment of patients with extrasystole in old and advanced age].
Butenko, AG; Korkuschko, OW; Schatilo, WB,
)
0.13
" The most frequently used dosage of mexiletine during each 3-month treatment period was 600 mg/day (50."( Chronic mexiletine therapy for suppression of ventricular arrhythmias.
Duke, M, 1988
)
0.98
" This dosage of propafenone did not provoke serious adverse effects in our patient."( Lidocaine, mexiletine and propafenone in the treatment of arrhythmias complicating myocardial infarction. A case report.
Aguglia, F; De Marzio, P; Gnecchi, M, 1985
)
0.66
" In conclusion, we recommend a slightly reduced dosage of 400-600 mg mexiletine/day (usually 600-800 mg) for patients with end-stage renal insufficiency, irrespective of dialysis."( [Mexiletine in terminal renal failure and various dialysis procedures].
Aboudan, F; Evers, J; Finke, K; Messer, W, 1989
)
1.42
" Serious adverse reactions necessitate a change in antiarrhythmic therapy, as opposed to lowering drug dosage to an ineffective level."( Antiarrhythmic drug therapy. Recent advances and current status.
Somberg, J, 1985
)
0.27
" Prolongation of ventricular depolarization has not been previously reported with the usual oral dosage of mexiletine."( Prolongation of ventricular depolarization. ECG manifestation of mexiletine toxicity.
Chandrasekaran, K; Hammill, SC; Nora, MO; Reeder, GS, 1989
)
0.73
" Thus, on a pharmacokinetic basis the loading dose of mexiletine need not be modified in cirrhotic patients, whereas the maintenance dosage should be reduced to one fourth - one third of the usual dose."( Cirrhosis of the liver markedly impairs the elimination of mexiletine.
Halinen, MO; Hietakorpi, S; Lampinen, LM; Pentikäinen, PJ, 1986
)
0.76
" Minor reactions were defined as those that required dosage reduction and major reactions as those that required drug discontinuation or permanent pacing for bradycardia."( Adverse reactions to antiarrhythmic drugs during therapy for ventricular arrhythmias.
Cook, TS; DiMarco, JP; Nygaard, TW; Sellers, TD, 1986
)
0.27
" Oral amiodarone was started using a loading dose of 600 mg daily for one week, 400 mg daily for one week, and a subsequent dosage of 200 mg daily five times a week."( [Anti-arrhythmic efficacy of the amiodarone-mexiletine combination in the treatment of resistant complex ventricular arrhythmias].
Bilancini, A; Blandini, A; Costantini, C; Curzi, G; Massacci, C; Pigini, G; Purcaro, A, 1986
)
0.53
"This paper describes a general approach to compute steady-state dosage regimens."( Steady-state dosage regimen calculations in linear pharmacokinetics.
Bruno, R; Cano, JP; Iliadis, A, 1986
)
0.27
" Thus dosing adjustments for mexiletine should not be necessary in patients with creatinine clearance values as low as 10 ml/min or in patients receiving dialysis."( Pharmacokinetics and nondialyzability of mexiletine in renal failure.
Stone, WJ; Wang, T; Woosley, RL; Wuellner, D, 1985
)
0.83
" Adjustment of drug dosage to achieve therapeutic blood levels resulted in an efficacy on ventricular ectopic rhythm similar to that obtained with the maximal tolerated dose."( Clinical evaluation of oral mexiletine therapy in the treatment of ventricular arrhythmias.
Amsterdam, EA; Harris, F; Rutledge, JC, 1985
)
0.56
" The results suggest that the dosage of mexiletine should be adjusted when enzyme inducing drugs are started or stopped during therapy with it."( Effect of rifampicin treatment on the kinetics of mexiletine.
Hiltunen, HA; Koivula, IH; Pentikäinen, PJ, 1982
)
0.78
" If side effects intervene that may cause continued therapy to be intolerable, changing the antiarrhythmic agent, as opposed to decreasing the dosage to an ineffective range, may be appropriate."( New directions in antiarrhythmic drug therapy.
Somberg, JC, 1984
)
0.27
"0 microgram/ml) could be maintained in patients admitted to a coronary care unit by twice daily dosing of a new slow-release (S."( Comparison of the plasma concentrations and efficacy of mexiletine and of a slow-release preparation of mexiletine in patients admitted to a coronary care unit.
Barber, JM; Boyle, DM; Chapman, C; Khalid, I; Kinney, CD; McIlmoyle, EL; Salathia, K; Shanks, RG,
)
0.38
" When ineffective, the serum mexiletine level can be estimated and when less than 1 microgram/ml, the dose may be increased, in particular by adjusting oral dosage to 200 mg six hourly."( [Anti-arrhythmic effects of mexiletine].
Besse, P; Favreau, L; Ledain, L; Page, A, 1982
)
0.85
" Studies bear out early reports of mexiletine as an effective antiarrhythmic drug nearly devoid of adverse hemodynamic effects when administered intravenously or orally in a dosage to maintain a therapeutic plasma concentration."( Hemodynamic effects of mexiletine.
Shanks, RG, 1984
)
0.86
" These side effects, although common, are frequently eliminated by reducing the dosage of the drug and administering the drug with food."( Oral mexiletine in the treatment of refractory ventricular arrhythmias: the role of electrophysiologic techniques.
Garan, H; McGovern, B; Ruskin, JN; Schoenfeld, MH; Whitford, E, 1984
)
0.78
"Measurement of drug levels is becoming increasingly popular to optimise the dosage of various drugs."( Reliability of antiarrhythmic drug plasma concentration monitoring.
Follath, F; Ganzinger, U; Schuetz, E,
)
0.13
" The dosage of encainide was increased from 25 to 75 mg three times daily and the antiarrhythmic effect monitored by repeated 24-h Holter registration and in some patients by treadmill exercise testing."( Increased incidence of side effects after encainide: a newly developed antiarrhythmic drug.
Berchtold-Kanz, E; Hust, M; Just, H; Nitsche, K; Schwarz, G, 1984
)
0.27
" These results suggest that mexiletine is effective against ventricular arrhythmias and the dosage should be carefully adjusted."( Pharmacokinetics and the antiarrhythmic effect of mexiletine in patients with chronic ventricular arrhythmias.
Ebihara, A; Hashimoto, T; Hosoda, S; Kondo, K; Ohashi, K; Oka, T, 1984
)
0.81
" On the last day of each treatment period frequent blood samples for drug assay were collected during a dosage interval."( A study to compare the efficacy, plasma concentration profile and tolerability of conventional mexiletine and slow-release mexiletine.
Holt, DW; Jackson, G; Upward, JW, 1984
)
0.49
" In the four volunteers, acute dosage with the 432-mg preparation produced a markedly lower peak mexiletine concentration and fewer side effects than did two 200-mg capsules."( Absorption and antiarrhythmic efficacy of sustained-release mexiletine.
Campbell, RW; Chadwick, DE; Holt, DW, 1983
)
0.73
" Whether the existence of a compromised renal, hepatic or cardiac function alters dosage requirements is not clear."( Adaptation of the dose of mexiletine according to pharmacokinetic data.
Bogaert, M, 1980
)
0.56
" The high incidence of side-effects was probably due to the high dosage used."( Evaluation of the antiarrhythmic efficacy of mexiletine in patients with chronic ventricular arrhythmias.
Van Durme, JP, 1980
)
0.52
" Thirty patients whose arrhythmia did not respond to correction of metabolic disturbances were randomly allocated to receive treatment either with lignocaine or with mexiletine in fixed dosage schedules (15 in each group)."( Mexiletine vs. lignocaine in the management of ventricular arrhythmias after open-heart surgery.
Bury, RW; Hale, G; Higginbotham, M; Mashford, ML; Zuidland, P, 1982
)
1.9
" The steady-state plasma concentrations of mexiletine in 5 patients, from whom blood samples were obtained as a measure of compliance, ranged between 570 to 1911 ng/ml which were similar to those reported from treatment of ventricular arrhythmias with similar dosage regimen of 200 mg mexiletine hydrochloride three times per day."( A modified gas-liquid chromatographic assay to monitor plasma mexiletine in a tinnitus study.
Chan, K; Pilling, M; Tse, J, 1982
)
0.77
" Based on these results, a dosage regimen is recommended which is expected to produce a "therapeutic" serum concentration (0."( Population pharmacokinetic parameters in patients treated with oral mexiletine.
Follath, F; Katz, G; Steiner, V; Vozeh, S, 1982
)
0.5
" The respective doses were 200 mg (intravenous infusion), 400 mg (two conventional capsules), and 432 mg (sustained-release dosage forms)."( Kinetics and bioavailability of mexiletine in healthy subjects.
Doevendans, JE; Häselbarth, V; Wolf, M, 1981
)
0.55
"In the course of this study, both the bioavailability and the most important pharmacokinetic parameters of a newly development mexiletine (CAS 31828-71-4) preparation (Mexiletine-ratiopharm mite, dosage 200 mg of mexiletine) were to be determined in comparison to a commercial reference preparation registered according to the AMG 1976, after single oral administration."( [The pharmacokinetics and bioavailability of a new mexiletine preparation in healthy volunteers].
Hutt, V; Jaeger, H; Kappler, J; Pabst, G; Salama, Z, 1995
)
0.75
" With an increase in dosage the efficacy does not rise proportionally."( [Mexiletine in treatment of painful diabetic neuropathy].
Armbrecht, U; Beroniade, S; Buch, KD; Federlin, K; Haupt, E; Husstedt, IW; Kampmann, B; Meyer, U; Schumacher, H; Stracke, H, 1994
)
1.2
" mexiletine, an orally active congener of lidocaine, on strychnine allodynia and compared the dose-response relationship of mexiletine in normal (noxious paw pinch) versus abnormal (i."( Comparable dose-dependent inhibition of AP-7 sensitive strychnine-induced allodynia and paw pinch-induced nociception by mexiletine in the rat.
Hodge, E; Khandwala, H; Loomis, CW, 1997
)
1.42
"Mexiletine in a dosage of 675 mg daily can reduce pain caused by diabetic neuropathy, and the effect of this drug appears to have a rapid onset."( Efficacy and safety of mexiletine in the treatment of painful diabetic neuropathy. The Mexiletine Study Group.
Lins, PE; Ljunggren, JG; Oskarsson, P, 1997
)
2.05
" These results should be useful for adjusting the dosage to a patient's age for the prevention of an adverse reaction caused by overexposure."( Population pharmacokinetic analysis of mexiletine in adult arrhythmic patients in Japanese population.
Iwai, T; Koue, T; Shibakawa, M; Uenaka, K; Ueno, K, 1998
)
0.57
" Therefore, the objective of this study was to assess the effects of a clinically relevant dosage of caffeine on the stereoselective disposition of mexiletine."( Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine.
Abolfathi, Z; Gilbert, M; Labbé, L; Robitaille, NM; St-Maurice, F; Turgeon, J, 1999
)
0.75
" Factors affecting the elimination of mexiletine may be clinically important and dosage adjustments are often necessary."( Clinical pharmacokinetics of mexiletine.
Labbé, L; Turgeon, J, 1999
)
0.87
" Subjects were followed on a weekly basis for dosing of mexiletine, blood levels, and completion of the Hamilton Depression Rating Scale (HAM-D) and the Manic State Rating Scale (MSRS)."( Mexiletine in treatment-resistant bipolar disorder.
Joffe, RT; Levitt, AJ; Schaffer, A,
)
1.82
" No adverse effects were reported in five patients; in one patient, dizziness developed at the dosage of 800 mg/d, requiring a reduction of the dose."( Mexiletine in the treatment of torticollis and generalized dystonia.
Bernardini, S; Bonuccelli, U; Brotini, S; Gambaccini, G; Lucetti, C; Manca, ML; Nuti, A,
)
1.57
"), a selective protein kinase C inhibitor, significantly inhibited intrathecal fenvalerate-induced nociceptive behavior with a rightward shift of the dose-response curve for fenvalerate-induced nociceptive behavior to the level those observed in non-diabetic mice."( Modification of the fenvalerate-induced nociceptive response in mice by diabetes.
Iguchi, E; Kamei, J; Morita, K; Sasaki, M; Tanaka, S; Zushida, K, 2002
)
0.31
"Oral mexiletine in a dosage of 300 mg daily suppresses persistent Na+ currents in human motor axons."( The effects of mexiletine on excitability properties of human median motor axons.
Hattori, T; Hiraga, A; Kanai, K; Kuwabara, S; Misawa, S; Nakata, M; Ogawara, K; Tamura, N, 2005
)
1.2
" The proposed method was successfully applied for accurate (mean recovery about 100%), precise (RSD about 1%) and selective determination of the studied drug in the pure and dosage forms."( Comparison of classical and derivative UV-spectrophotometric methods for the quantification of diltiazem and mexiletine.
Hopkała, H; Kowalczuk, D; Pietraś, R,
)
0.34
" Three months later the dosage was reduced to 100 mg mexiletine and 25 mg Amitriptyline daily."( [An uncommon cause of recurrent abdominal pain in a 63-year-old obese woman].
Schuppert, F; Tiesmeier, J; Warnecke, H, 2006
)
0.58
" Compound 4 had good efficacy (52% and 41% reversal of allodynia at 2 and 4h post-dose, respectively) in the Chung rat spinal nerve ligation (SNL) model of neuropathic pain when dosed orally at 10mg/kg."( Imidazopyridines: a novel class of hNav1.7 channel blockers.
Abbadie, C; Dean, B; Duffy, JL; Felix, JP; Garcia, ML; Hoyt, SB; Jochnowitz, N; Kaczorowski, GJ; Karanam, BV; Li, X; London, C; Lyons, KA; Martin, WJ; McGowan, E; Parsons, WH; Priest, BT; Smith, MM; Tschirret-Guth, R; Warren, VA; Williams, BS, 2008
)
0.35
"Drugs were tested in a repeated dosing paradigm (four daily injections)."( Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies.
Bennett, GJ; Naso, L; Xiao, W,
)
0.13
" A simple and effective on-line dilution approach was adopted in order to expand the linearity and apply the method to assay, dosage uniformity and dissolution tests with minimum sample preparation."( Novel automated assay for the quality control of mexiletine hydrochloride formulations using sequential injection and on-line dilution.
Rigas, P; Tzanavaras, PD; Zacharis, CK, 2008
)
0.6
" Treatment with mexiletine at either dosage was not associated with any serious adverse events, or with prolongation of the PR or QTc intervals or of QRS duration."( Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.
Annis, CL; Barbieri, CA; Dilek, N; Logigian, EL; Martens, WB; McDermott, MP; Moxley, RT; Pearson, AT; Thornton, CA; Wiegner, AW, 2010
)
2.15
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" In one patient, severe hypoglycemia limited dosing to 500 mg daily, but this was sufficient for VT control."( Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.
Anderson, JL; Bair, TL; Bunch, TJ; Crandall, BG; Day, JD; Lappe, DL; Mader, KM; Mahapatra, S; May, HT; Molden, J; Muhlestein, JB; Murdock, D; Osborn, JS; Weiss, JP, 2011
)
0.37
"Telemetered dogs were orally dosed with quinidine (class Ia), mexiletine (class Ib) or flecainide (class Ic)."( Detecting drug-induced prolongation of the QRS complex: new insights for cardiac safety assessment.
Cros, C; Lainee, P; Moors, J; Skinner, M; Valentin, JP, 2012
)
0.62
" Animals in the control (n = 6 for each blood collection time), diabetic (single intravenous dosage of 45 mg·(kg body mass)(-1) of streptozotocin), and insulin-treated groups (diabetic rats treated daily with 2 IU insulin) received by gavage a single dose of 10 mg·(kg body mass)(-1) racemic MEX."( Influence of experimental diabetes and insulin treatment on the enantioselective pharmacokinetics of mexiletine and its metabolites.
Barbosa Coelho, E; de Carvalho Leone, A; Lucia Lanchote, V; Marques, MP; Martinez, EZ; Pardo Campos Godoy, AL, 2014
)
0.62
"Active pharmaceutical ingredients (APIs) can be prepared in many different solid forms and phases that affect their physicochemical properties and suitability for oral dosage forms."( Rapid Characterization of Formulated Pharmaceuticals Using Fast MAS
Carnahan, SL; Hirsh, DA; Hung, I; Lubach, JW; Nagapudi, K; Rossini, AJ; Wijesekara, AV, 2019
)
0.51
" This is a retrospective case series of 10 cancer patients across four institutions, with attention to dosing of both agents, and subsequent decrease in morphine-equivalent daily dosing (MEDD)."( A Multi-Centered Case Series Highlighting the Clinical Use and Dosing of Lidocaine and Mexiletine for Refractory Cancer Pain.
Atayee, RS; Edmonds, KP; Geiger-Hayes, J; Hausdorff, J; Naidu, D; Saphire, ML, 2020
)
0.78
" The rate of side effects requiring dosage reduction or interruption was not neglectable."( Mexiletine for ventricular arrhythmias in patients with chronic coronary syndrome: a cohort study.
Bilato, C; Cavedon, S; Mecenero, A; Mugnai, G; Paolini, C; Perrone, C, 2022
)
2.16
"Consensus was achieved for key questions including the average long-term dosage of mexiletine (NaMuscla) in practice, the criteria for eligibility of myotonia treatment, the clinical importance of QoL outcomes in MYOMEX, the higher proportion of patients with increased QoL, and the reduction in the need for mental health resources for patients receiving mexiletine (NaMuscla)."( Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel.
Chapman, AM; Ellis, C; Lee, H; Omar, A; Schneider-Gold, C; Schurer, M; Sonecha, S; Weidenfeller, AZ; Weijers, L, 2021
)
1.06
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
primary amino compoundA compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Mexiletine Action Pathway478

Protein Targets (32)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 2D6Homo sapiens (human)Potency21.31740.00108.379861.1304AID1645840
D(1A) dopamine receptorHomo sapiens (human)Potency0.65130.02245.944922.3872AID488982
chromobox protein homolog 1Homo sapiens (human)Potency28.18380.006026.168889.1251AID488953
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency2.39340.425612.059128.1838AID504536
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency8.49210.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium channel subfamily K member 3Homo sapiens (human)IC50 (µMol)97.30000.00700.89855.1000AID1307734
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)IC50 (µMol)100.00000.00032.63119.0000AID1207189
Potassium channel subfamily K member 2Homo sapiens (human)IC50 (µMol)173.00000.40003.92279.0000AID1307730
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
Sodium channel protein type 1 subunit alphaRattus norvegicus (Norway rat)IC50 (µMol)47.00000.01001.14052.9390AID179553
Sodium channel protein type 2 subunit alphaRattus norvegicus (Norway rat)IC50 (µMol)47.00000.00401.14854.7300AID179553
Sodium channel protein type 3 subunit alphaRattus norvegicus (Norway rat)IC50 (µMol)47.00000.00600.86052.9390AID179553
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)50.00000.00002.800510.0000AID1210069
Sodium channel protein type 1 subunit alphaHomo sapiens (human)IC50 (µMol)43.00000.00232.82969.0000AID1207160
Sodium channel protein type 4 subunit alphaHomo sapiens (human)IC50 (µMol)43.00000.00013.507510.0000AID1207160
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)1.13800.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.72400.00030.769310.0000AID625217
Cytochrome P450 2J2Homo sapiens (human)IC50 (µMol)50.00000.01202.53129.4700AID1210069
Sodium channel protein type 7 subunit alphaHomo sapiens (human)IC50 (µMol)43.00000.03603.73359.0000AID1207160
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)IC50 (µMol)100.00000.00032.59559.0000AID1207189
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)10.00000.00091.901410.0000AID1207219; AID576612
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)IC50 (µMol)100.00000.00032.63119.0000AID1207189
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)100.00000.00032.25459.6000AID1207189
Sodium channel protein type 5 subunit alphaHomo sapiens (human)IC50 (µMol)107.40000.00033.64849.2000AID1207160; AID1754522; AID404536; AID655925; AID655926
Sodium channel protein type 9 subunit alphaHomo sapiens (human)IC50 (µMol)11,290.00000.00602.77499.0000AID1207160; AID314412; AID612180; AID612189; AID640525
Sodium channel protein type 9 subunit alphaHomo sapiens (human)Ki13.00000.36000.43000.5000AID612078
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Sodium channel protein type 2 subunit alphaHomo sapiens (human)IC50 (µMol)22.95000.00003.740110.0000AID1207160; AID404535
Sodium channel protein type 3 subunit alphaHomo sapiens (human)IC50 (µMol)43.00000.00532.80859.0000AID1207160
Sodium channel protein type 11 subunit alphaHomo sapiens (human)IC50 (µMol)43.00000.03004.36959.0000AID1207160
Sodium channel protein type 8 subunit alphaHomo sapiens (human)IC50 (µMol)43.00000.00113.47059.0000AID1207160
Sodium channel protein type 10 subunit alphaHomo sapiens (human)IC50 (µMol)49.50000.00803.17529.0000AID1207160; AID404534
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (252)

Processvia Protein(s)Taxonomy
potassium ion transportPotassium channel subfamily K member 3Homo sapiens (human)
chemical synaptic transmissionPotassium channel subfamily K member 3Homo sapiens (human)
response to xenobiotic stimulusPotassium channel subfamily K member 3Homo sapiens (human)
monoatomic ion transmembrane transportPotassium channel subfamily K member 3Homo sapiens (human)
negative regulation of cytosolic calcium ion concentrationPotassium channel subfamily K member 3Homo sapiens (human)
regulation of resting membrane potentialPotassium channel subfamily K member 3Homo sapiens (human)
cellular response to zinc ionPotassium channel subfamily K member 3Homo sapiens (human)
cellular response to hypoxiaPotassium channel subfamily K member 3Homo sapiens (human)
cochlea developmentPotassium channel subfamily K member 3Homo sapiens (human)
potassium ion transmembrane transportPotassium channel subfamily K member 3Homo sapiens (human)
stabilization of membrane potentialPotassium channel subfamily K member 3Homo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
cardiac ventricle developmentPotassium channel subfamily K member 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayPotassium channel subfamily K member 2Homo sapiens (human)
memoryPotassium channel subfamily K member 2Homo sapiens (human)
response to mechanical stimulusPotassium channel subfamily K member 2Homo sapiens (human)
response to axon injuryPotassium channel subfamily K member 2Homo sapiens (human)
negative regulation of cardiac muscle cell proliferationPotassium channel subfamily K member 2Homo sapiens (human)
cellular response to hypoxiaPotassium channel subfamily K member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium channel subfamily K member 2Homo sapiens (human)
cochlea developmentPotassium channel subfamily K member 2Homo sapiens (human)
positive regulation of cellular response to hypoxiaPotassium channel subfamily K member 2Homo sapiens (human)
negative regulation of DNA biosynthetic processPotassium channel subfamily K member 2Homo sapiens (human)
stabilization of membrane potentialPotassium channel subfamily K member 2Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
sodium ion transportSodium channel protein type 1 subunit alphaHomo sapiens (human)
adult walking behaviorSodium channel protein type 1 subunit alphaHomo sapiens (human)
determination of adult lifespanSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuronal action potential propagationSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
nerve developmentSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuromuscular process controlling postureSodium channel protein type 1 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painSodium channel protein type 1 subunit alphaHomo sapiens (human)
establishment of localization in cellSodium channel protein type 1 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 1 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
regulation of presynaptic membrane potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 1 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 4 subunit alphaHomo sapiens (human)
muscle contractionSodium channel protein type 4 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 4 subunit alphaHomo sapiens (human)
regulation of skeletal muscle contraction by action potentialSodium channel protein type 4 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 4 subunit alphaHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
fatty acid metabolic processCytochrome P450 2J2Homo sapiens (human)
icosanoid metabolic processCytochrome P450 2J2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2J2Homo sapiens (human)
regulation of heart contractionCytochrome P450 2J2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2J2Homo sapiens (human)
linoleic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
organic acid metabolic processCytochrome P450 2J2Homo sapiens (human)
osmosensory signaling pathwaySodium channel protein type 7 subunit alphaHomo sapiens (human)
response to bacteriumSodium channel protein type 7 subunit alphaHomo sapiens (human)
cellular homeostasisSodium channel protein type 7 subunit alphaHomo sapiens (human)
sodium ion homeostasisSodium channel protein type 7 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 7 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 7 subunit alphaHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
sensory perception of soundVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion importVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transporter activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
skeletal system developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
extraocular skeletal muscle developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
striated muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
endoplasmic reticulum organizationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
myoblast fusionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle adaptationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle fiber developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
release of sequestered calcium ion into cytosolVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cellular response to caffeineVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rateSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac conduction system developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac ventricle developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
brainstem developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
response to denervation involved in regulation of muscle adaptationSodium channel protein type 5 subunit alphaHomo sapiens (human)
telencephalon developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cerebellum developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of epithelial cell proliferationSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cellular response to calcium ionSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of cardiac muscle cell contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
ventricular cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell to bundle of His cell communicationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 9 subunit alphaHomo sapiens (human)
inflammatory responseSodium channel protein type 9 subunit alphaHomo sapiens (human)
circadian rhythmSodium channel protein type 9 subunit alphaHomo sapiens (human)
response to toxic substanceSodium channel protein type 9 subunit alphaHomo sapiens (human)
post-embryonic developmentSodium channel protein type 9 subunit alphaHomo sapiens (human)
sensory perception of painSodium channel protein type 9 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 9 subunit alphaHomo sapiens (human)
behavioral response to painSodium channel protein type 9 subunit alphaHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of painSodium channel protein type 9 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perceptionSodium channel protein type 9 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 9 subunit alphaHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
sodium ion transportSodium channel protein type 2 subunit alphaHomo sapiens (human)
nervous system developmentSodium channel protein type 2 subunit alphaHomo sapiens (human)
intrinsic apoptotic signaling pathway in response to osmotic stressSodium channel protein type 2 subunit alphaHomo sapiens (human)
neuron apoptotic processSodium channel protein type 2 subunit alphaHomo sapiens (human)
memorySodium channel protein type 2 subunit alphaHomo sapiens (human)
determination of adult lifespanSodium channel protein type 2 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 2 subunit alphaHomo sapiens (human)
dentate gyrus developmentSodium channel protein type 2 subunit alphaHomo sapiens (human)
nerve developmentSodium channel protein type 2 subunit alphaHomo sapiens (human)
myelinationSodium channel protein type 2 subunit alphaHomo sapiens (human)
cellular response to hypoxiaSodium channel protein type 2 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 2 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 2 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 3 subunit alphaHomo sapiens (human)
behavioral response to painSodium channel protein type 3 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 3 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 3 subunit alphaHomo sapiens (human)
thigmotaxisSodium channel protein type 11 subunit alphaHomo sapiens (human)
acute inflammatory responseSodium channel protein type 11 subunit alphaHomo sapiens (human)
chronic inflammatory responseSodium channel protein type 11 subunit alphaHomo sapiens (human)
axonogenesisSodium channel protein type 11 subunit alphaHomo sapiens (human)
circadian rhythmSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to heatSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to xenobiotic stimulusSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to toxic substanceSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to high light intensitySodium channel protein type 11 subunit alphaHomo sapiens (human)
protein kinase A signalingSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to auditory stimulusSodium channel protein type 11 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 11 subunit alphaHomo sapiens (human)
sensory perception of painSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to prostaglandin ESodium channel protein type 11 subunit alphaHomo sapiens (human)
thermosensory behaviorSodium channel protein type 11 subunit alphaHomo sapiens (human)
mast cell degranulationSodium channel protein type 11 subunit alphaHomo sapiens (human)
cell motilitySodium channel protein type 11 subunit alphaHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of painSodium channel protein type 11 subunit alphaHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painSodium channel protein type 11 subunit alphaHomo sapiens (human)
reflexSodium channel protein type 11 subunit alphaHomo sapiens (human)
micturitionSodium channel protein type 11 subunit alphaHomo sapiens (human)
skeletal muscle organ developmentSodium channel protein type 11 subunit alphaHomo sapiens (human)
artery developmentSodium channel protein type 11 subunit alphaHomo sapiens (human)
behavioral response to acetic acid induced painSodium channel protein type 11 subunit alphaHomo sapiens (human)
behavioral response to formalin induced painSodium channel protein type 11 subunit alphaHomo sapiens (human)
cellular response to coldSodium channel protein type 11 subunit alphaHomo sapiens (human)
calcium ion transmembrane transportSodium channel protein type 11 subunit alphaHomo sapiens (human)
response to nitric oxideSodium channel protein type 11 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 11 subunit alphaHomo sapiens (human)
action potential initiationSodium channel protein type 11 subunit alphaHomo sapiens (human)
sensory perception of itchSodium channel protein type 11 subunit alphaHomo sapiens (human)
calcitonin gene-related peptide receptor signaling pathwaySodium channel protein type 11 subunit alphaHomo sapiens (human)
small intestine smooth muscle contractionSodium channel protein type 11 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 11 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 11 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 8 subunit alphaHomo sapiens (human)
nervous system developmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
peripheral nervous system developmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
neuronal action potentialSodium channel protein type 8 subunit alphaHomo sapiens (human)
optic nerve developmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
myelinationSodium channel protein type 8 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 8 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 8 subunit alphaHomo sapiens (human)
regulation of heart rateSodium channel protein type 10 subunit alphaHomo sapiens (human)
sensory perceptionSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of monoatomic ion transmembrane transportSodium channel protein type 10 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 10 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of cardiac muscle contractionSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 10 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
regulation of presynaptic membrane potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 10 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (93)

Processvia Protein(s)Taxonomy
monoatomic ion channel activityPotassium channel subfamily K member 3Homo sapiens (human)
open rectifier potassium channel activityPotassium channel subfamily K member 3Homo sapiens (human)
potassium channel activityPotassium channel subfamily K member 3Homo sapiens (human)
potassium ion leak channel activityPotassium channel subfamily K member 3Homo sapiens (human)
S100 protein bindingPotassium channel subfamily K member 3Homo sapiens (human)
outward rectifier potassium channel activityPotassium channel subfamily K member 3Homo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
outward rectifier potassium channel activityPotassium channel subfamily K member 2Homo sapiens (human)
potassium ion leak channel activityPotassium channel subfamily K member 2Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 1 subunit alphaHomo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialSodium channel protein type 1 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 4 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 4 subunit alphaHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
monooxygenase activityCytochrome P450 2J2Homo sapiens (human)
iron ion bindingCytochrome P450 2J2Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
isomerase activityCytochrome P450 2J2Homo sapiens (human)
linoleic acid epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
hydroperoxy icosatetraenoate isomerase activityCytochrome P450 2J2Homo sapiens (human)
arachidonic acid 5,6-epoxygenase activityCytochrome P450 2J2Homo sapiens (human)
heme bindingCytochrome P450 2J2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2J2Homo sapiens (human)
sodium channel activitySodium channel protein type 7 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 7 subunit alphaHomo sapiens (human)
osmolarity-sensing monoatomic cation channel activitySodium channel protein type 7 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 7 subunit alphaHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
ankyrin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
small molecule bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
molecular function activator activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibroblast growth factor bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
enzyme bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein kinase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein domain specific bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ankyrin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
nitric-oxide synthase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
scaffold protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 9 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 9 subunit alphaHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 2 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 2 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 2 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 3 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 11 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 8 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 8 subunit alphaHomo sapiens (human)
ATP bindingSodium channel protein type 8 subunit alphaHomo sapiens (human)
sodium ion bindingSodium channel protein type 8 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 10 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 10 subunit alphaHomo sapiens (human)
voltage-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potentialSodium channel protein type 10 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (62)

Processvia Protein(s)Taxonomy
plasma membranePotassium channel subfamily K member 3Homo sapiens (human)
synapsePotassium channel subfamily K member 3Homo sapiens (human)
plasma membranePotassium channel subfamily K member 3Homo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
photoreceptor outer segmentVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
endoplasmic reticulum membranePotassium channel subfamily K member 2Homo sapiens (human)
plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
cell surfacePotassium channel subfamily K member 2Homo sapiens (human)
apical plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
neuronal cell bodyPotassium channel subfamily K member 2Homo sapiens (human)
calyx of HeldPotassium channel subfamily K member 2Homo sapiens (human)
astrocyte projectionPotassium channel subfamily K member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium channel subfamily K member 2Homo sapiens (human)
plasma membranePotassium channel subfamily K member 2Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneSodium channel protein type 1 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 1 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 1 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 1 subunit alphaHomo sapiens (human)
nuclear bodySodium channel protein type 1 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 1 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 1 subunit alphaHomo sapiens (human)
node of RanvierSodium channel protein type 1 subunit alphaHomo sapiens (human)
neuronal cell bodySodium channel protein type 1 subunit alphaHomo sapiens (human)
axon initial segmentSodium channel protein type 1 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 1 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 4 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 4 subunit alphaHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2J2Homo sapiens (human)
extracellular exosomeCytochrome P450 2J2Homo sapiens (human)
cytoplasmCytochrome P450 2J2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2J2Homo sapiens (human)
plasma membraneSodium channel protein type 7 subunit alphaHomo sapiens (human)
glial cell projectionSodium channel protein type 7 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 7 subunit alphaHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
sarcoplasmic reticulumVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
T-tubuleVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
I bandVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleolusSodium channel protein type 5 subunit alphaHomo sapiens (human)
endoplasmic reticulumSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell surfaceSodium channel protein type 5 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 5 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
lateral plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 5 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 5 subunit alphaHomo sapiens (human)
sarcolemmaSodium channel protein type 5 subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 9 subunit alphaHomo sapiens (human)
axonSodium channel protein type 9 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 9 subunit alphaHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
plasma membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 2 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 2 subunit alphaHomo sapiens (human)
axonSodium channel protein type 2 subunit alphaHomo sapiens (human)
node of RanvierSodium channel protein type 2 subunit alphaHomo sapiens (human)
paranode region of axonSodium channel protein type 2 subunit alphaHomo sapiens (human)
presynaptic membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
glutamatergic synapseSodium channel protein type 2 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 2 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 2 subunit alphaHomo sapiens (human)
sarcoplasmSodium channel protein type 3 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 3 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 11 subunit alphaHomo sapiens (human)
axonSodium channel protein type 11 subunit alphaHomo sapiens (human)
neuronal cell bodySodium channel protein type 11 subunit alphaHomo sapiens (human)
axonal growth coneSodium channel protein type 11 subunit alphaHomo sapiens (human)
C-fiberSodium channel protein type 11 subunit alphaHomo sapiens (human)
extracellular exosomeSodium channel protein type 11 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 11 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 8 subunit alphaHomo sapiens (human)
cell junctionSodium channel protein type 8 subunit alphaHomo sapiens (human)
axonSodium channel protein type 8 subunit alphaHomo sapiens (human)
cytoplasmic vesicleSodium channel protein type 8 subunit alphaHomo sapiens (human)
node of RanvierSodium channel protein type 8 subunit alphaHomo sapiens (human)
axon initial segmentSodium channel protein type 8 subunit alphaHomo sapiens (human)
presynaptic active zone membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
parallel fiber to Purkinje cell synapseSodium channel protein type 8 subunit alphaHomo sapiens (human)
postsynaptic density membraneSodium channel protein type 8 subunit alphaHomo sapiens (human)
glutamatergic synapseSodium channel protein type 8 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 8 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 10 subunit alphaHomo sapiens (human)
axonSodium channel protein type 10 subunit alphaHomo sapiens (human)
presynaptic membraneSodium channel protein type 10 subunit alphaHomo sapiens (human)
extracellular exosomeSodium channel protein type 10 subunit alphaHomo sapiens (human)
glutamatergic synapseSodium channel protein type 10 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 10 subunit alphaHomo sapiens (human)
clathrin complexSodium channel protein type 10 subunit alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (222)

Assay IDTitleYearJournalArticle
AID404541Toxicity against ip dosed Sprague-Dawley rat at 460 umol/kg2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1750987Inhibition of potassium channel (unknown origin) expressed in CHO cells assessed as reduction in potassium current by automated patch clamp method2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID404540Effect on locomotor activity in ip dosed Sprague-Dawley rat2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID408762Anticonvulsant activity against maximal electroshock-induced seizures in mouse model2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Synthesis and anticonvulsant activity of aromatic tetramethylcyclopropanecarboxamide derivatives.
AID226359Displacement of [3H]BTX from sodium channel of rat cerebral cortex synaptosomes2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID655930Antiarrhythmic activity in guinea pig left atria assessed as increase of 1 Hz-induced alternating current arrhythmia at 10'-4 M after 60 mins relative to control2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1751003Half life in Sprague-Dawley rat at 25 mg/kg, po measured upto 25 hrs by LCMS analysis2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1734579Toxicity in rabbit model of left circumflex artery ligation-induced ischemia assessed as animal death at 1 mg/kg2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1307734Inhibition of of TASK1 (unknown origin) expressed in CHO cells assessed as reduction in channel currents2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID753331Analgesic activity in po dosed rat spinal nerve ligation neuropathic pain model assessed as reversal of allodynia measured at 2 to 4 hrs2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic pain.
AID1751000AUC in Sprague-Dawley rat at 5 mg/kg, iv measured upto 25 hrs by LCMS analysis2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID1720724Anticonvulsant activity in ip dosed albino mouse assessed as protection against 50 mA current-induced seizure by maximal electroshock seizure test
AID655946Apparent permeability from basolateral to apical side in human Caco2 cells after 21 days by UV spectroscopy2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1463746Effect on electrical threshold for nociceptive flexion reflex in mouse assessed as A-delta current threshold at 10 mg/kg, ip measured every 15 min up to 1 hr (Rvb = 0.2 mA)2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Discovery of non-zwitterionic aryl sulfonamides as Na
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID655942Vasorelaxant activity in potassium depolarized guinea pig aortic strip assessed as inhibition of calcium-induced contraction at 10'-4 M2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1750982Antiarrhythmic activity in hiPSC-CMs assessed as prolongation of action potential2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID759296Elimination half life in human2013European journal of medicinal chemistry, Jul, Volume: 65Searching for new antiarrhythmic agents: evaluation of meta-hydroxymexiletine enantiomers.
AID1750980Antiarrhythmic activity in hiPSC-CMs assessed as cessation dose of cell beating2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID655931Antiarrhythmic activity in guinea pig left atria assessed as increase of 1 Hz-induced alternating current arrhythmia after 60 mins2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
AID655941Negative chronotropic activity in guinea pig spontaneously beating right atria assessed as decrease in atrial rate2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
AID1750977Antiarrhythmic activity in patient-derived hiPSC-CMs carrying LQT3 mutation assessed as shortening of action potential duration2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID640525Antagonist activity at 20% inactivated human sodium channel Nav1.7 expressed in human HEK293 cells by patch-clamp electrophysiological assay2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Discovery and optimization of aminopyrimidinones as potent and state-dependent Nav1.7 antagonists.
AID8002Observed volume of distribution2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID29925Volume of distribution in man (IV dose)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1751005Drug metabolism assessed as human CYP3A4-mediated metabolism per ug protein2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID314421Analgesic activity in rat assessed as reversal of allodynia in chung model of neuropathic apin at 10 mg/kg, po after 4 hrs2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Imidazopyridines: a novel class of hNav1.7 channel blockers.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1307730Inhibition of of human TREK1 expressed in CHO cells assessed as reduction in channel currents2016Journal of medicinal chemistry, 06-09, Volume: 59, Issue:11
Perspectives on the Two-Pore Domain Potassium Channel TREK-1 (TWIK-Related K(+) Channel 1). A Novel Therapeutic Target?
AID1751001AUC in Sprague-Dawley rat at 25 mg/kg, po measured upto 25 hrs by LCMS analysis2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID1750998Cmax in Sprague-Dawley rat at 5 mg/kg, iv measured upto 25 hrs by LCMS analysis2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID1750985Inhibition of sodium channel (unknown origin) expressed in HEK cells assessed as reduction in late inward sodium current by automated patch clamp method2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID612189Inhibition of 20% inactivated human sodium channel Nav1.7 expressed in human HEK293 cells by patch-clamp electrophysiological assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.
AID1636356Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID655936Negative inotropic activity in guinea pig left atria assessed as decrease of 1 Hz current-induced developed tension at 10'-5 M relative to control2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID129483Inhibition of chloroform induced ventricular arrhythmia1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Synthesis and antiarrhythmic activity of 5,11-dihydro[1]benzoxepino[3,4-b]pyridines.
AID404534Inhibition of human recombinant Nav1.8 channel expressed in HEK293 cells by whole cell voltage clamp technique2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.
AID759289Relaxtant activity in guinea pig K+-depolarized ileum longitudinal smooth muscle assessed as inhibition of calcium-induced contraction2013European journal of medicinal chemistry, Jul, Volume: 65Searching for new antiarrhythmic agents: evaluation of meta-hydroxymexiletine enantiomers.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID655926Blockade of human full-length NaV1.5 expressed in HEK293 cells co-transfected with pCD8-IRES-hbeta1 assessed as 10 Hz of use-dependent-induced channel current at -120 mV holding potential after 36 to 72 hrs by patch clamp assay2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1751002Half life in Sprague-Dawley rat at 5 mg/kg, iv measured upto 25 hrs by LCMS analysis2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID612078Binding affinity to inactivated human sodium channel Nav1.7 expressed in human HEK293 cells by patch-clamp electrophysiological assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID612180Inhibition of fully inactivated human sodium channel Nav1.7 expressed in human HEK293 cells by patch-clamp electrophysiological assay2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.
AID310080Reversal of allodynia in rat at 30 mg/kg, po after 2 hrs2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain.
AID753328Neurotoxicity in rat assessed as reduction in latency time at => 10 mg/kg, po after 2 hrs by rotarod test relative to vehicle-treated control2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic pain.
AID404533Blockade of Nav1.8 channel in rat dorsal root ganglion neurons assessed as inhibition of TTX-R current by whole cell patch clamp technique2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.
AID759287Drug excretion in myocardial infarction patient urine at 200 t 300 mg, po tid measured for 48 hrs relative to control2013European journal of medicinal chemistry, Jul, Volume: 65Searching for new antiarrhythmic agents: evaluation of meta-hydroxymexiletine enantiomers.
AID1750984Antiarrhythmic activity in hiPSC-CMs assessed as fold prolongation of action potential relative to control2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID655943Neurotoxicity in mouse assessed as deffect in motor coordination at 25 to 50 mg/kg, po after 15 to 45 mins by rotarod test2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1754522Inhibition of Nav1.5 (unknown origin)-mediated late channel current2021Bioorganic & medicinal chemistry letters, 08-01, Volume: 45Identification of aryl sulfonamides as novel and potent inhibitors of Na
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID74902Amount of ouabain needed for production of ventricular fibrillation at a dose of 4 mg/kg (iv given 5 min prior) in guinea pig1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
New antiarrhythmic agents. 2,2,5,5-Tetramethyl-3-pyrroline-3-carboxamides and 2,2,5,5-tetramethylpyrrolidine-3-carboxamindes.
AID127965Dose required to double the prodrug pupil size1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Synthesis and antiarrhythmic activity of 5,11-dihydro[1]benzoxepino[3,4-b]pyridines.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID29337Ionisation constant (pKa)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID612077Ratio of Ki for resting human sodium channel Nav1.7 expressed in human HEK293 cells to Ki for inactivated human sodium channel Nav1.7 expressed in human HEK293 cells2011Journal of medicinal chemistry, Jul-14, Volume: 54, Issue:13
Identification of a potent, state-dependent inhibitor of Nav1.7 with oral efficacy in the formalin model of persistent pain.
AID1285789Anticonvulsant activity in ip dosed mouse assessed as protection against maximal electric shock-induced seizures2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID28233Fraction ionized (pH 7.4)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID318437Inhibition of Nav1.8 channel in rat dorsal root ganglion neurons assessed as blockade of TTX-R current by patch clamp method2007Proceedings of the National Academy of Sciences of the United States of America, May-15, Volume: 104, Issue:20
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.
AID414885Electrophysiological effect in New Zealand rabbit right ventricular papillary muscle assessed as resting membrane potential at 20 um at 1 Hz stimulation frequency2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
5,7,8-Trimethyl-benzopyran and 5,7,8-trimethyl-1,4-benzoxazine aminoamide derivatives as novel antiarrhythmics against ischemia-reperfusion injury.
AID141948Inhibitory effect on muscarinic acetylcholine receptor binding affinity at a concentration of (10e -6)M1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Synthesis and antiarrhythmic activity of 5,11-dihydro[1]benzoxepino[3,4-b]pyridines.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1750999Cmax in Sprague-Dawley rat at 25 mg/kg, po measured upto 25 hrs by LCMS analysis2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID141947Inhibitory effect on muscarinic acetylcholine receptor binding affinity at a concentration of (10e -5)M1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Synthesis and antiarrhythmic activity of 5,11-dihydro[1]benzoxepino[3,4-b]pyridines.
AID310081Reversal of allodynia in rat at 30 mg/kg, po after 4 hrs2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain.
AID230972Ratio of the concentrations of tonic block to that of phasic block2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Optically active mexiletine analogues as stereoselective blockers of voltage-gated Na(+) channels.
AID414886Electrophysiological effect in New Zealand rabbit right ventricular papillary muscle assessed as action potential amplitude at 20 uM at 1 Hz stimulation frequency2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
5,7,8-Trimethyl-benzopyran and 5,7,8-trimethyl-1,4-benzoxazine aminoamide derivatives as novel antiarrhythmics against ischemia-reperfusion injury.
AID1750989Selectivity index, ratio of IC50 for potassium channel (unknown origin) expressed in HEK cells assessed as reduction in potassium current to IC50 for sodium channel (unknown origin) expressed in HEK cells assessed as reduction in late inward sodium curren2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID1207219Inhibition of hERG K channel2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID184913Percent inhibition of veratridine-induced glutamate release in rat brain slices at 10000 nmol/L; ND is No Data.2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1383102Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes at 200 uM after 7 days by hemocytometry2018European journal of medicinal chemistry, Apr-10, Volume: 149Identification of cisapride as new inhibitor of putrescine uptake in Trypanosoma cruzi by combined ligand- and structure-based virtual screening.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1750981Antiarrhythmic activity in hiPSC-CMs assessed as dose for induction of early after depolarizations2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID26362Ionization constant (pKa)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID179553Inhibitory effect against veratridine-induced glutamate release from rat brain slices2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1720725Anticonvulsant activity in ip dosed Swiss mouse assessed as protection against current-induced seizure by maximal electroshock seizure test
AID1210069Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method2013Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 41, Issue:1
Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID314412Blockade of human Nav1.7 channel expressed in HEK293 cells by FRET assay2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Imidazopyridines: a novel class of hNav1.7 channel blockers.
AID753342Analgesic activity in rat spinal nerve ligation neuropathic pain model assessed as reversal of allodynia at 30 mg/kg, po measured at 2 hrs relative to control2013Bioorganic & medicinal chemistry letters, Jun-15, Volume: 23, Issue:12
A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic pain.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID165937Half-maximal concentration producing a tonic block (blocking sodium channels at resting conditions during infrequent depolarizing pulses) in Rana esculenta muscle2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Optically active mexiletine analogues as stereoselective blockers of voltage-gated Na(+) channels.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID314420Analgesic activity in rat assessed as reversal of allodynia in chung model of neuropathic pain at 10 mg/kg, po after 2 hrs2008Bioorganic & medicinal chemistry letters, Mar-01, Volume: 18, Issue:5
Imidazopyridines: a novel class of hNav1.7 channel blockers.
AID1734554Toxicity in rabbit model of left circumflex artery ligation-induced ischemia assessed as increase in VT-VF at 1 mg/kg by electrocardiographic analysis2016Journal of medicinal chemistry, Oct-13, Volume: 59, Issue:19
Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I
AID7783Unbound fraction (plasma)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
AID28236Unbound fraction (tissues)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1750976Antiarrhythmic activity in patient-derived hiPSC-CMs carrying LQT3 mutation assessed as cessation dose for cell beating2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID1750978Antiarrhythmic activity in patient-derived hiPSC-CMs carrying LQT3 mutation assessed as fold shortening of action potential duration relative to control2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1750997Tmax in Sprague-Dawley rat at 25 mg/kg, po measured upto 25 hrs by LCMS analysis2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID62548No. of cases tested was measured on ouabain induced ventricular arrhythmia at 5 mg/kg, iv in dogs; 5/81990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Synthesis and antiarrhythmic activity of 5,11-dihydro[1]benzoxepino[3,4-b]pyridines.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID404546Ratio of drug level in brain to plasma in Sprague-Dawley rat2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1751006Drug metabolism assessed as human CYP3A5-mediated metabolism per ug protein2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID655925Blockade of human full-length NaV1.5 expressed in HEK293 cells co-transfected with pCD8-IRES-hbeta1 assessed as 0.1 Hz of half-maximal tonic-induced channel current at -120 mV holding potential after 36 to 72 hrs by patch clamp assay2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
AID759288Relaxtant activity in guinea pig K+-depolarized ileum longitudinal smooth muscle assessed as inhibition of calcium-induced contraction at 10'-4 M relative to control2013European journal of medicinal chemistry, Jul, Volume: 65Searching for new antiarrhythmic agents: evaluation of meta-hydroxymexiletine enantiomers.
AID1463732Anti-nociceptive activity in mouse model of formalin-induced persistent pain assessed as reversal of phase-2 nociceptive behaviors occurring during 15 to 45 mins at 30 mg/kg, po dosed 30 mins before formalin challenge2017Bioorganic & medicinal chemistry, 10-15, Volume: 25, Issue:20
Discovery of non-zwitterionic aryl sulfonamides as Na
AID28235Unbound fraction (plasma)2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1207250Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1383107Inhibition of Trypanosoma cruzi Y epimastigotes PAT12 assessed as reduction in initial velocity of [14C]-putrescine uptake at 50 uM in presence of non-radioactive putrescine by liquid scintillation counting method2018European journal of medicinal chemistry, Apr-10, Volume: 149Identification of cisapride as new inhibitor of putrescine uptake in Trypanosoma cruzi by combined ligand- and structure-based virtual screening.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1751007Drug metabolism assessed as human CYP2D6-mediated metabolism per ug protein2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID781328pKa (acid-base dissociation constant) as determined by Luan ref: Pharm. Res. 20052014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID1207160Inhibition of Na channel (species unknown)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID414887Electrophysiological effect in New Zealand rabbit right ventricular papillary muscle assessed as action potential duration measured at 50% repolarization at 20 uM at 1 Hz stimulation frequency2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
5,7,8-Trimethyl-benzopyran and 5,7,8-trimethyl-1,4-benzoxazine aminoamide derivatives as novel antiarrhythmics against ischemia-reperfusion injury.
AID404538Analgesic activity in ip dosed Sprague-Dawley rat assessed as attenuation of mechanical allodynia in chung model of neuropathic pain2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.
AID625277FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID404536Inhibition of human recombinant Nav1.5 channel expressed in HEK293 cells by whole cell voltage clamp technique2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1415343Anticonvulsant activity in ip dosed mouse assessed as protection against maximal electroshock-induced seizures2017MedChemComm, Jan-01, Volume: 8, Issue:1
Design, synthesis and anticonvulsant-analgesic activity of new
AID74899Amount of ouabain needed for production of ventricular extra-systoles at a dose of 4 mg/kg (iv given 5 min prior) in guinea pig1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
New antiarrhythmic agents. 2,2,5,5-Tetramethyl-3-pyrroline-3-carboxamides and 2,2,5,5-tetramethylpyrrolidine-3-carboxamindes.
AID1750979Antiarrhythmic activity in patient-derived hiPSC-CMs carrying LQT3 mutation assessed as shortening dose of action potential2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID624618Specific activity of expressed human recombinant UGT2B42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1207189Inhibition of voltage-gated L-type Ca channel (species unknown)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID404535Inhibition of human recombinant Nav1.2 channel expressed in HEK293 cells by whole cell voltage clamp technique2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID414890Electrophysiological effect in New Zealand rabbit right ventricular papillary muscle assessed as maximal rate of depolarization at 20 uM at 1 Hz stimulation frequency2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
5,7,8-Trimethyl-benzopyran and 5,7,8-trimethyl-1,4-benzoxazine aminoamide derivatives as novel antiarrhythmics against ischemia-reperfusion injury.
AID1662996Inhibition of human Nav1.7 expressed in CHO cells at 300 uM with -120 mV holding potential by whole cell manual patch clamp method2020Journal of medicinal chemistry, 09-24, Volume: 63, Issue:18
Discovery of DS-1971a, a Potent, Selective Na
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID232386Ratio of ED100 (Dose po required to double the prodrug pupil size in mice) to that of ED50 (50% inhibition of chloroform induced ventricular arrhythmia in mice)1990Journal of medicinal chemistry, Nov, Volume: 33, Issue:11
Synthesis and antiarrhythmic activity of 5,11-dihydro[1]benzoxepino[3,4-b]pyridines.
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID655949Negative chronotropic activity in guinea pig spontaneously beating right atria assessed as decrease in atrial rate at 10'-7 M relative to control2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID655947Efflux ratio of permeability from basolateral to apical side to apical to basolateral side in human Caco2 cells after 21 days by UV spectroscopy2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
AID165936Half-maximal concentration producing a phasic block (cumulative sodium current reduction at 10 HZ stimulation frequency) in Rana esculenta muscle2003Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24
Optically active mexiletine analogues as stereoselective blockers of voltage-gated Na(+) channels.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID74896Amount of ouabain needed for production of ventricular arrhythmias that causes death in guinea pig by cardiac arrest at a dose of 4 mg/kg iv given 5 min prior1986Journal of medicinal chemistry, Jul, Volume: 29, Issue:7
New antiarrhythmic agents. 2,2,5,5-Tetramethyl-3-pyrroline-3-carboxamides and 2,2,5,5-tetramethylpyrrolidine-3-carboxamindes.
AID1751004Oral bioavailability in Sprague-Dawley rat at 25 mg/kg measured upto 25 hrs by LCMS analysis2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID655940Negative inotropic activity in guinea pig left atria assessed as decrease of 1 Hz current-induced developed tension2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
AID655944Cytotoxicity against human HepG2 cells assessed as cell viability after 2 hrs by MTT assay2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
AID226365Displacement of [3H]-MK-801 from rat cerebral cortex glutamate NMDA receptor; ND is No Data.2002Journal of medicinal chemistry, Aug-15, Volume: 45, Issue:17
Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke.
AID404543Analgesic activity in ip dosed Sprague-Dawley rat by rotarod test2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Discovery of potent furan piperazine sodium channel blockers for treatment of neuropathic pain.
AID1750986Inhibition of sodium channel (unknown origin) expressed in HEK cells assessed as reduction in peak sodium current by automated patch clamp method2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID414888Electrophysiological effect in New Zealand rabbit right ventricular papillary muscle assessed as action potential duration measured at 90% repolarization at 20 uM at 1 Hz stimulation frequency2009Journal of medicinal chemistry, Apr-23, Volume: 52, Issue:8
5,7,8-Trimethyl-benzopyran and 5,7,8-trimethyl-1,4-benzoxazine aminoamide derivatives as novel antiarrhythmics against ischemia-reperfusion injury.
AID781326pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X2014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID29423HPLC capacity factor (k')2002Journal of medicinal chemistry, Jun-20, Volume: 45, Issue:13
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
AID624615Specific activity of expressed human recombinant UGT2B102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID197266In vivo anticonvulsant activity to prevent seizures from maximum electroshock (MES) in rat hippocampal slices2001Journal of medicinal chemistry, Jan-18, Volume: 44, Issue:2
Medicinal chemistry of neuronal voltage-gated sodium channel blockers.
AID655945Apparent permeability from apical to basolateral side in human Caco2 cells after 21 days by UV spectroscopy2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Synthesis and toxicopharmacological evaluation of m-hydroxymexiletine, the first metabolite of mexiletine more potent than the parent compound on voltage-gated sodium channels.
AID1750996Tmax in Sprague-Dawley rat at 5 mg/kg, iv measured upto 25 hrs by LCMS analysis2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
Antiarrhythmic Hit to Lead Refinement in a Dish Using Patient-Derived iPSC Cardiomyocytes.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346737Human Nav1.4 (Voltage-gated sodium channels)2004The Journal of physiology, Feb-01, Volume: 554, Issue:Pt 3
Mexiletine block of wild-type and inactivation-deficient human skeletal muscle hNav1.4 Na+ channels.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,372)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990573 (41.76)18.7374
1990's321 (23.40)18.2507
2000's227 (16.55)29.6817
2010's180 (13.12)24.3611
2020's71 (5.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 83.58

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index83.58 (24.57)
Research Supply Index7.44 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index152.03 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (83.58)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials210 (14.11%)5.53%
Reviews121 (8.13%)6.00%
Case Studies208 (13.98%)4.05%
Observational1 (0.07%)0.25%
Other948 (63.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (25)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Antiarrhythmic Therapy Versus Catheter Ablation as First Line Treatment for AICD Shock Prevention: A Randomized Vanguard Pilot Trial [NCT02114528]Phase 440 participants (Anticipated)Interventional2014-10-31Terminated(stopped due to Low recruitment. Pilot trial.)
Potential of Late Na Current Blocker Mexilate on Giant T-wave Electrical Alternans and Subsequent Ventricular Arrhythmias: a Multicenter, Randomized, Prospective Study [NCT05619120]50 participants (Anticipated)Interventional2023-01-01Recruiting
A Phase III, Randomised, Double Blinded, Head-to-head, Single-site, Cross-over Trial of Lamotrigine Versus Mexiletine for Non-dystrophic Myotonias [NCT05017155]Phase 360 participants (Anticipated)Interventional2021-08-12Recruiting
Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of Mexiletine in Paediatric Patients With Myotonic Disorders Who Have Completed the MEX-NM-301 Study. [NCT04622553]14 participants (Anticipated)Interventional2021-11-05Recruiting
Combining N-of-1 Trials to Estimate Population Clinical and Cost-effectiveness of Drugs Using Bayesian Hierarchical Modeling. The Case of Mexiletine for Patients With Non- Dystrophic Myotonia. [NCT02045667]Phase 230 participants (Actual)Interventional2014-01-31Completed
Treatment of Myotonia - Lamotrigine Versus Namuscla [NCT05639257]32 participants (Anticipated)Interventional2022-12-05Recruiting
A Phase II/III Double-Blind Study of Amitriptyline and Mexiletine for Painful Neuropathy in HIV Infection [NCT00000793]Phase 2240 participants InterventionalCompleted
An Open-label, Non-Comparative Study to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of Mexiletine in Adolescents and Children With Myotonic Disorders [NCT04624750]Phase 314 participants (Anticipated)Interventional2021-09-03Recruiting
Phase II Therapeutic Trial of Mexiletine in Non-Dystrophic Myotonia [NCT00832000]Phase 259 participants (Actual)Interventional2008-12-31Completed
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Investigate the Efficacy and Safety of Mexiletine During 26 Weeks of Treatment in Patients With Myotonic Dystrophy Type 1 and Type 2 [The MIND Study] [NCT04700046]Phase 30 participants (Actual)Interventional2023-08-06Withdrawn(stopped due to Assessing novel alternative study designs and regulatory pathways)
A Safety and Tolerability Study of Mexiletine in Patients With Sporadic Amyotrophic Lateral Sclerosis (SALS) [NCT01849770]Phase 275 participants (Actual)Interventional2013-07-31Completed
Randomized, Placebo-Controlled, Double-Blind Cross-Over Trial of Opioids Versus Mexiletine in the Treatment of Postamputation Pain [NCT00383682]Phase 260 participants Interventional1997-07-31Completed
Mexiletine for the Treatment of Muscle Cramps in ALS [NCT01811355]Phase 423 participants (Actual)Interventional2013-05-31Completed
[NCT00000464]Phase 30 participants Interventional1987-04-30Completed
[NCT00000518]Phase 30 participants Interventional1985-07-31Completed
Mexiletine for the Treatment of Focal Dystonia [NCT00001784]Phase 224 participants Interventional1998-07-31Completed
An Observational Study to Describe the Long-term Safety and Effectiveness of Namuscla in the Symptomatic Management of Myotonia in Adult Patients With Non-dystrophic Myotonic Disorders [NCT04616807]53 participants (Actual)Observational2020-12-17Active, not recruiting
Effects of Mexiletine on Colonic Transit in a Patient With a Known SCN5A A997T Mutation [NCT01717404]Phase 11 participants (Actual)Interventional2012-10-31Completed
Effect of Mexiletine on Cortical Hyperexcitability in Sporadic Amyotrophic Lateral Sclerosis (SALS) [NCT02781454]Phase 220 participants (Actual)Interventional2016-10-31Completed
Five Period Crossover Study of the Ability of Late Sodium or Calcium Current Block (Mexiletine, Lidocaine, or Diltiazem) to Balance the Electrocardiographic Effects of hERG Potassium Current Block (Dofetilide or Moxifloxacin) [NCT02308748]Phase 122 participants (Actual)Interventional2014-05-31Completed
[NCT00004647]Phase 340 participants Interventional1993-03-31Completed
Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease [NCT02561702]Phase 24 participants (Actual)Interventional2015-09-30Completed
Efficacy and Safety of Mexiletine in Non-dystrophic Myotonias [NCT02336477]Phase 324 participants (Actual)Interventional2011-06-30Completed
A Randomized, Placebo Controlled, Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type-1 (DM1) [NCT01406873]Phase 242 participants (Actual)Interventional2011-06-30Completed
Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations (PAIN-CONTRoLS) [NCT02260388]Phase 4402 participants (Actual)Interventional2014-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00832000 (14) [back to overview]Clinical Eye Closure Myotonia Evaluation (Seconds)
NCT00832000 (14) [back to overview]Clinical Hand Grip Myotonia Evaluation (Seconds)
NCT00832000 (14) [back to overview]Compound Motor Action Potentials After Long Exercise Test
NCT00832000 (14) [back to overview]Compound Motor Action Potentials After Short Exercise Test
NCT00832000 (14) [back to overview]Graded Myotonia by Needle Electromyography - Right Abductor Digiti Minimi
NCT00832000 (14) [back to overview]Graded Myotonia by Needle Electromyography - Right Tibialis Anterior
NCT00832000 (14) [back to overview]Individualized Neuromuscular Quality of Life Scale - Summary Score
NCT00832000 (14) [back to overview]Patient Reported Pain on the IVR
NCT00832000 (14) [back to overview]Patient Reported Tiredness on the IVR
NCT00832000 (14) [back to overview]Patient Reported Weakness on the IVR
NCT00832000 (14) [back to overview]Patient-reported Stiffness on the IVR
NCT00832000 (14) [back to overview]Quantitative Measure of Hand Grip Myotonia (Seconds)
NCT00832000 (14) [back to overview]Short Form 36 - Mental Composite Score
NCT00832000 (14) [back to overview]Short Form 36 - Physical Composite Score
NCT01406873 (6) [back to overview]Mean Change From Baseline in Quantitative Measure of Hand Grip Myotonia
NCT01406873 (6) [back to overview]Mean Change From Baseline in Ambulation Using the 6 Minute Walk Distance
NCT01406873 (6) [back to overview]Mean Change From Baseline in Manual Muscle Testing (MMT) Score
NCT01406873 (6) [back to overview]Mean Change From Baseline in Patient-Reported Disease Burden and Quality of Life
NCT01406873 (6) [back to overview]Mean Change From Baseline in PR, QRS, and QTc Intervals, and Average Minimum Heart Rate (HR) Via Electrocardiogram (ECG) Monitoring
NCT01406873 (6) [back to overview]Percentage of Participants That Had a Dose Reduction or a Study Drug Withdrawal or Suspension Over 6 Months
NCT01811355 (2) [back to overview]Cramp Severity
NCT01811355 (2) [back to overview]Daily Muscle Cramps
NCT01849770 (13) [back to overview]Change in Slow Vital Capacity (SVC) Score
NCT01849770 (13) [back to overview]Maximal Pain Severity
NCT01849770 (13) [back to overview]Maximal Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12
NCT01849770 (13) [back to overview]Mean Pain Severity
NCT01849770 (13) [back to overview]Mean Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12
NCT01849770 (13) [back to overview]Mean Weekly Cramp Frequency
NCT01849770 (13) [back to overview]Cramp Frequency - Ratios for Comparisons of Doses for Weeks 3-12
NCT01849770 (13) [back to overview]Area Under the Concentration Time Curve (AUC) of Mexiletine in Plasma.
NCT01849770 (13) [back to overview]Mean Cerebrospinal Fluid (CSF)/Plasma Ratio
NCT01849770 (13) [back to overview]Peak Plasma Concentration (Cmax) of Mexiletine
NCT01849770 (13) [back to overview]Percentage of Participants That Discontinued Study Drug
NCT01849770 (13) [back to overview]Trough Plasma Concentration (Cmin) of Mexiletine
NCT01849770 (13) [back to overview]Change in ALS Functional Rating Scale- Revised (ALSFRS-R) Score
NCT02260388 (4) [back to overview]SF12 Health Composite Scores
NCT02260388 (4) [back to overview]PROMIS Fatigue Short Form v1.0 8a
NCT02260388 (4) [back to overview]PROMIS Pain Interference Short Form v1.0 8a T Score
NCT02260388 (4) [back to overview]PROMIS Sleep Disturbance Short Form v1.0 8a
NCT02308748 (2) [back to overview]Change in Placebo Corrected Change From Baseline QTc Interval on the ECG Measured in Milliseconds When Moxifloxacin is Administered With Diltiazem at the Evening Dose Compared to When Moxifloxacin is Administered Alone at Afternoon Dose on Treatment Day.
NCT02308748 (2) [back to overview]Change in Placebo Corrected Change From Baseline QTc and J-Tpeakc Intervals on the ECG Measured in Milliseconds When Dofetilide is Administered With Mexiletine or Lidocaine Compared to When Dofetilide is Administered Alone at Evening Dose on Treatment Day
NCT02561702 (2) [back to overview]Number of Participants With a Decrease in Cramp Duration
NCT02561702 (2) [back to overview]Number of Participants With a Decrease in Cramp Intensity
NCT02781454 (13) [back to overview]Effect on Frequency of Muscle Cramps
NCT02781454 (13) [back to overview]Effect on Hyperpolarizing Threshold Electrotonus (90-100 ms)
NCT02781454 (13) [back to overview]Effect on Short-interval Intracortical Inhibition
NCT02781454 (13) [back to overview]Effect on Strength Duration Time Constant
NCT02781454 (13) [back to overview]Effect on Subexcitability
NCT02781454 (13) [back to overview]Effect on Superexcitability
NCT02781454 (13) [back to overview]Change in Motor Evoked Potential Amplitude
NCT02781454 (13) [back to overview]Change in Slow Vital Capacity
NCT02781454 (13) [back to overview]Change in the Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised
NCT02781454 (13) [back to overview]Effect on Cortical Silent Period
NCT02781454 (13) [back to overview]Effect on Depolarizing Threshold Electrotonus (90-100 ms)
NCT02781454 (13) [back to overview]Effect on Frequency of Fasciculations (Muscle Twitching)
NCT02781454 (13) [back to overview]Change in Resting Motor Threshold

Clinical Eye Closure Myotonia Evaluation (Seconds)

Time to open the eyes after forced eye closure as measured on a stopwatch. (NCT00832000)
Timeframe: The end of period 1 (week 4) and the end of period 2 (week 9)

InterventionSeconds (Mean)
Mexiletine0.161
Placebo0.474

[back to top]

Clinical Hand Grip Myotonia Evaluation (Seconds)

The time to open the fist after a forced handgrip as measured on a stopwatch. (NCT00832000)
Timeframe: The end of period 1 (week 4) and the end of period 2 (week 9)

InterventionSeconds (Mean)
Mexiletine0.164
Placebo0.494

[back to top]

Compound Motor Action Potentials After Long Exercise Test

Compound muscle action potential (CMAP) after long periods of exercise as a percentage of baseline. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)

Interventionpercentage of baseline CMAP amplitude (Mean)
Mexiletine81.8
Placebo80.1

[back to top]

Compound Motor Action Potentials After Short Exercise Test

The maximal post-exercise compound muscle action potential (CMAP) after short periods of exercise as a percent of the baseline measurement. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)

Interventionpercentage of baseline CMAP amplitude (Mean)
Mexiletine83.1
Placebo78.6

[back to top]

Graded Myotonia by Needle Electromyography - Right Abductor Digiti Minimi

Measured the amount of myotonia present on needle exam by assigning a number 1-3, with 1 being minimal amount of myotonia on needle stick and 3 being maximal amount of myotonia present on needle stick. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)

Interventionunits on a scale (Mean)
Mexiletine2.05
Placebo2.62

[back to top]

Graded Myotonia by Needle Electromyography - Right Tibialis Anterior

Measured the amount of myotonia present on needle exam by assigning a number 1-3, with 1 being minimal amount of myotonia on needle stick and 3 being maximal amount of myotonia present on needle stick. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)

Interventionunits on a scale (Mean)
Mexiletine2.07
Placebo2.54

[back to top]

Individualized Neuromuscular Quality of Life Scale - Summary Score

Quality of life scale for patinets with neuromuscular disorders. The INQoL summary score is a weighted average made up of 5 subdomains (activities, social relationships, independence, emotions, and body image) which document the impact of a disease on a patients' quality of life. Scores range from 0-100, and can be interpreted as the percent of maximal detrimental impact on quality of life. A higher score indicates more detrimental impact. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)

Interventionunits on a scale (Mean)
Mexiletine14.0
Placebo16.7

[back to top]

Patient Reported Pain on the IVR

Pain measured on a 1-9 scale, 1 being minimal, 9 the worst ever experienced. 0=no symptom reported. For analysis the average severity of pain for each participant was calculated from daily calls made in weeks 3-4 of each period. (NCT00832000)
Timeframe: Weeeks 3-4 of each period

Interventionunits on a scale (Mean)
Mexiletine1.54
Placebo3.17

[back to top]

Patient Reported Tiredness on the IVR

Tiredness measured on a 1-9 scale, 1 being minimal, 9 the worst ever experienced. 0=no symptom reported. For analysis the average severity of tiredness for each participant was calculated from daily calls made in weeks 3-4 of each period. (NCT00832000)
Timeframe: Weeks 3-4 of each period

Interventionunits on a scale (Mean)
Mexiletine2.90
Placebo3.82

[back to top]

Patient Reported Weakness on the IVR

Weakness measured on a 1-9 scale, 1 being minimal, 9 the worst ever experienced. 0=no symptom reported. For analysis the average severity of weakness for each participant was calculated from daily calls made in weeks 3-4 of each period. (NCT00832000)
Timeframe: Weeks 3-4 of each period

Interventionunits on a scale (Mean)
Mexiletine1.96
Placebo3.22

[back to top]

Patient-reported Stiffness on the IVR

Stiffness measured on a 1-9 scale, 1 being minimal, 9 the worst ever experienced. 0=no symptom reported. For analysis the average severity of stiffness for each participant was calculated from daily calls made in weeks 3-4 of each period. (NCT00832000)
Timeframe: Weeks 3-4 of each period

Interventionunits on a scale (Mean)
Mexiletine - Period 12.53
Placebo - Period 14.21
Mexiletine - Period 21.60
Placebo - Period 25.27

[back to top]

Quantitative Measure of Hand Grip Myotonia (Seconds)

Maximum voluntary contractions following forced right hand grip were recorded and the time to relax from 90% to 5% of average maximal force was determined using automated analysis software. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)

Interventionseconds (Mean)
Mexiletine0.321
Placebo0.429

[back to top]

Short Form 36 - Mental Composite Score

The SF-36 is a standard quality of life instrument. The mental composite score represents the the mental burden on quality of life and is a summary of questions related to mental impact of a disease or condition (mental function, role emotional, vitality, and mental health). The score is nomralized to the population and ranges from 0-100, with the US normal value of 50. A lower score represents a greater impact of quality of life. (NCT00832000)
Timeframe: The end of period 1 (week 4) and period 2 (week 9)

Interventionunits on a scale (Mean)
Mexiletine - Period 147.4
Placebo - Period 147.7
Mexiletine - Period 253.1
Placebo - Period 242.7

[back to top]

Short Form 36 - Physical Composite Score

The SF-36 is a standard quality of life instrument. The physical composite score represents the the physical burden on quality of life and is a summary of questions related to physical impact of a disease or condition (physical function, role physical, bodily pain, and general health). The score is nomralized to the population and ranges from 0-100, with the US normal value of 50. A lower score represents a greater impact of quality of life. (NCT00832000)
Timeframe: Particiapnts who experienced weakness on mexiletine in either period 1 or period 2.

Interventionunits on a scale (Mean)
Mexiletine44.8
Placebo39.2

[back to top]

Mean Change From Baseline in Quantitative Measure of Hand Grip Myotonia

Relaxation time of the long finger flexor muscles of the right hand after a maximum voluntary isometric contraction performed in a standardized fixed position of the right arm elbow/wrist/hand. Relaxation time for this measurement is defined as the time to relax from 90% to 5% of the maximum isometric force of contraction of the hand (the first of 6 serial contractions averaged over two consecutive trials performed 10 minutes apart). (NCT01406873)
Timeframe: Baseline to 6 months

InterventionSeconds (Mean)
Mexiletine-1.01
Placebo0.43

[back to top]

Mean Change From Baseline in Ambulation Using the 6 Minute Walk Distance

During this assessment, participants were asked to walk as far as they could back and forth on a fixed 20 meter route for 6 minutes. The total distance walked during the 6 minutes was recorded in meters. Change from baseline was defined as the difference between the average 6 minute walk distance at baseline and the average 6 minute walk distance at 6 months. (NCT01406873)
Timeframe: Baseline to 6 months

InterventionMeters (Mean)
Mexiletine17.44
Placebo7.25

[back to top]

Mean Change From Baseline in Manual Muscle Testing (MMT) Score

Manual muscle testing was performed on 26 muscle groups (shoulder abductors, elbow flexors, wrist flexors, wrist extensors, hip flexors, knee extensors, hip extensors, knee flexors, hip abductors, elbow extensors, ankle dorsiflexors, and plantar flexors on the right and left plus neck extensor and neck flexors). The muscles were tested in various positions including sitting, supine, prone, and side lying and each graded on a modification of the Medical Research Council (MRC) scale of 0 to 5 (5 representing normal strength). Average MMT score is derived by averaging the individual MMT scores across the 26 individual muscles. (NCT01406873)
Timeframe: Baseline to 6 months

InterventionUnits on a scale (Mean)
Mexiletine0.05
Placebo-0.06

[back to top]

Mean Change From Baseline in Patient-Reported Disease Burden and Quality of Life

"The Myotonic Dystrophy Health Index (MDHI) is a validated disease-specific measure of patient-reported disease burden. The MDHI total score is a weighted average derived from 17 subscales. MDHI total scores range form 0-100 with 0 representing no patient-reported disease burden and 100 representing the most severe patient-reported disease burden.~The Individualized Neuromuscular Quality of Life Questionnaire (INQoL) is a measure of quality of life in neuromuscular disease. The INQoL summary score is a weighted average made up of 5 sub-domains. Scores range from 0-100, and can be interpreted as the percent of maximal detrimental impact on quality of life with higher scores indicating more detrimental impact.~The 36-Item Short Form Survey (SF-36) is a generic measure of quality of life across 8 domains. Two summary metrics are produced from the 8 domains, ranging from 0-100% with lower scores representing worse levels of functioning." (NCT01406873)
Timeframe: Baseline to 6 months

,
InterventionUnits on a scale (Mean)
INQoLMDHISF-36 Physical Component SummarySF-36 Mental Component Summary
Mexiletine5.110.01-1.73-0.62
Placebo2.33-1.10-1.35-0.79

[back to top]

Mean Change From Baseline in PR, QRS, and QTc Intervals, and Average Minimum Heart Rate (HR) Via Electrocardiogram (ECG) Monitoring

PR, QRS, and QTc intervals as well as average minimum heart rate (HR) were obtained through standard 12 lead electrocardiograms (ECGs). Values were computer generated and verified by the study investigator and study cardiologist. (NCT01406873)
Timeframe: Baseline to 6 Months

,
InterventionMilliseconds (Mean)
PR IntervalQRS IntervalQTc IntervalAverage Minimum Heart Rate
Mexiletine11.350.70-4.400.65
Placebo8.891.00-1.55-0.25

[back to top]

Percentage of Participants That Had a Dose Reduction or a Study Drug Withdrawal or Suspension Over 6 Months

Adverse events were monitored at the three in-person evaluations (Months 0, 3, and 6), at telephone evaluations every 2 weeks, and via patient-completed side effect diaries. The study investigators and safety monitoring committee reviewed adverse events and made decisions regarding drug withdrawals, suspensions, and dose reductions as needed. (NCT01406873)
Timeframe: 6 months

,
InterventionParticipants (Count of Participants)
Study Drug WithdrawalStudy Drug Dose ReductionStudy Drug Temporary Suspension
Mexiletine211
Placebo000

[back to top]

Cramp Severity

Daily cramp severity was rated on the 100-unit visual analog scale. Scores ranged from 0 to 100, with 100 being the greatest amount of cramp severity (NCT01811355)
Timeframe: 6 weeks

,
Interventionunits on a scale (Mean)
Placebo DoseMexiletine DoseDifference Between
Mexiletine First43.623.120.5
Placebo First44.732.812.0

[back to top]

Daily Muscle Cramps

The average of the daily recording of number of muscle cramps that occurred in the last 24 hours- over a 6 week period. (NCT01811355)
Timeframe: 6 weeks

,
InterventionCramps per 24 hours (Mean)
Placebo DoseMexiletine DoseDifference Between
Mexiletine First/Placebo Second6.14.91.2
Placebo First/Mexiletine Second4.72.52.2

[back to top]

Change in Slow Vital Capacity (SVC) Score

The vital capacity (VC) (percent of predicted normal) will be determined, using the slow VC method. The SVC can be measured using conventional spirometers that have had a calibration check prior to subject testing. A printout from the spirometer of all SVC trials will be retained. (NCT01849770)
Timeframe: Week 0, Week 6, and Week 12 (or Early Termination Date)

,,
Interventionpercent of predicted normal (Mean)
Week 0 n=20,19,20Week 6 n=20,19,20Week 12 n=20,19,20
Mexiletine, 300 Milligrams87.7486.5183.98
Mexiletine, 900 Milligrams87.7482.9277.18
Placebo87.7484.7979.58

[back to top]

Maximal Pain Severity

"At the Baseline Visit, subjects will be asked to recount the maximum intensity experienced with a muscle cramp in the previous 24 hours and the maximum intensity experienced with a muscle cramp in the previous 30 days.~The visual analog scale (VAS) will be used to measures pain associated with muscle cramping. It will be used to measure muscle cramp intensity in this study. The scale rating is from 0-10; 0 equals no symptoms, 10 equals most severe symptoms.~Subject will be provided with a muscle cramp diary to record muscle cramp intensity at home, daily." (NCT01849770)
Timeframe: Weeks 3-12, post titration of study medication

,,
Interventionunits on a scale (Mean)
All Subjects n=20,19,2010+cramps previous 30 days at Baseline n=20,19,20
Mexiletine, 300 Milligrams0.7381.348
Mexiletine, 900 Milligrams0.3400.572
Placebo0.9392.033

[back to top]

Maximal Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12

(NCT01849770)
Timeframe: Week 3-12, post titration of study medication

,
Interventionratio (Number)
All Subjects n=20,1910+cramps previous 30 days at Baseline n=20,19
300mg vs Placebo0.7850.663
900mg vs Placebo0.3610.281

[back to top]

Mean Pain Severity

"At the Baseline Visit, subjects will be asked to recount the maximum intensity experienced with a muscle cramp in the previous 24 hours and the maximum intensity experienced with a muscle cramp in the previous 30 days.~The visual analog scale (VAS) will be used to measures pain associated with muscle cramping. It will be used to measure muscle cramp intensity in this study. The scale rating is from 0-10; 0 equals no symptoms, 10 equals most severe symptoms.~Subject will be provided with a muscle cramp diary to record muscle cramp intensity at home, daily." (NCT01849770)
Timeframe: Weeks 3-12, post titration of study medication

,,
Interventionunits on a scale (Mean)
All Subjects n=20,19,2010+cramps previous 30 days at Baseline n=20,19,20
Mexiletine, 300 Milligrams0.2410.467
Mexiletine, 900 Milligrams0.1360.201
Placebo0.5361.248

[back to top]

Mean Pain Severity - Ratios for Comparisons of Doses for Weeks 3-12

(NCT01849770)
Timeframe: Week 3-12, post titration of study medication

,
Interventionratio (Number)
All Subjects n=20,1910+cramps previous 30 days at Baseline n=20,19
300mg vs Placebo0.4500.374
900mg vs Placebo0.2540.161

[back to top]

Mean Weekly Cramp Frequency

(NCT01849770)
Timeframe: Week 3-12, post titration of study medication

,,
Interventioncramps/week (Mean)
All Subjects n=20,19,2010+cramps previous 30 days at Baseline n=20,19,20
Mexiletine, 300 Milligrams0.7851.898
Mexiletine, 900 Milligrams0.2310.595
Placebo2.5058.563

[back to top]

Cramp Frequency - Ratios for Comparisons of Doses for Weeks 3-12

(NCT01849770)
Timeframe: Week 3-12, post titration of study medication

,
Interventionratio (Number)
All Subjects n=20,1910+cramps previous 30 days at Baseline n=20,19
300mg vs Placebo0.3130.222
900mg vs Placebo0.1580.069

[back to top]

Area Under the Concentration Time Curve (AUC) of Mexiletine in Plasma.

Subjects will have blood drawn to assess mexiletine concentrations for pharmacokinetics (PK) at the Week 6 Visit. (NCT01849770)
Timeframe: Week 6 Visit (up to 6 hours post dose)

Interventionµg*hr/mL (Mean)
Mexiletine, 300 Milligrams2.34
Mexiletine, 900 Milligrams6.24
Placebo0

[back to top]

Mean Cerebrospinal Fluid (CSF)/Plasma Ratio

The concentrations of Mexiletine were measured in cerebrospinal fluid (CSF) and plasma. (NCT01849770)
Timeframe: Week 6 Visit (up to 6 hours post dose)

Interventionratio (Mean)
Mexiletine, 300 Milligrams0.38
Mexiletine, 900 Milligrams0.46
Placebo0

[back to top]

Peak Plasma Concentration (Cmax) of Mexiletine

Subjects will have blood drawn to assess mexiletine concentrations for pharmacokinetics (PK) at the Week 6 Visit. (NCT01849770)
Timeframe: Week 6 Visit (pre-dose, hours 1, 2, 3, and 6 post-dose on Week 6)

Interventionpg/mL (Mean)
Mexiletine, 300 Milligrams0.41
Mexiletine, 900 Milligrams1.27
Placebo0

[back to top]

Percentage of Participants That Discontinued Study Drug

Information on adverse effects of mexiletine will be determined at each visit by direct questioning of the subjects, clinical examination, review of concomitant medications, vital signs and laboratory test results. (NCT01849770)
Timeframe: Screening, Baseline Visit Pre-Dose and Post-Dose, Weeks 2, 6, and 12, and at the Final Safety Visit, if a subject discontinues study drug early. Adverse Events will be assessed via telephone Weeks 1, 10, and 16.

Interventionpercentage of participants (Number)
Mexiletine, 300 Milligrams5
Mexiletine, 900 Milligrams32
Placebo5

[back to top]

Trough Plasma Concentration (Cmin) of Mexiletine

Subjects will have blood drawn to assess mexiletine concentrations for pharmacokinetics (PK) at the Week 6 Visit. (NCT01849770)
Timeframe: Week 6 Visit (pre-dose, hours 1, 2, 3, and 6 post-dose on Week 6)

Interventionpg/mL (Mean)
Mexiletine, 300 Milligrams0.23
Mexiletine, 900 Milligrams0.68
Placebo0

[back to top]

Change in ALS Functional Rating Scale- Revised (ALSFRS-R) Score

The ALSFRS-R is a quickly administered (5 minutes) ordinal rating scale (ratings 0-4) used to determine subjects' assessment of their capability and independence in 12 functional activities. All 12 activities are relevant in ALS. Initial validity was established by documenting that in ALS patients, change in ALSFRS-R scores correlated with change in strength over time, was closely associated with quality of life measures, and predicted survival. (NCT01849770)
Timeframe: Week 0, Week 2, Week 6, Week 12 (or Early Termination Date), and Week 16

,,
Interventionscores on a scale (Mean)
Week 0 n=20,19,20Week 2 n=20,19,20Week 6 n=20,19,20Week 12 n=20,19,20Week 16 n=20,19,20
Mexiletine, 300 Milligrams35.2135.1435.7233.3332.44
Mexiletine, 900 Milligrams35.2134.5833.0831.8531.94
Placebo35.2135.4734.2533.4832.96

[back to top]

SF12 Health Composite Scores

"SF-12v2® Health Survey Standard The Optum™ SF-12v2® Health Survey is a shorter version of the SF-36v2® Health Survey that uses just 12 questions to measure functional health and well-being from the patient's point of view.~Survey provides psychometrically-based physical component summary (PCS) and mental component summary (MCS) scores.~Scores are calibrated so that 50 is the average score or norm, standard deviation = 10.~Higher scores indicate better health for both mental and physical component summary scores." (NCT02260388)
Timeframe: 12 weeks

,,,
InterventionNorm-Based Standardization Score (Mean)
Mental Component ScorePhysical Component Score
Duloxetine50.942.1
Mexiletine51.343.7
Nortriptyline51.042.8
Pregabalin47.240.0

[back to top]

PROMIS Fatigue Short Form v1.0 8a

"Higher scores for fatigue represents worse outcome (more fatigue). T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population." (NCT02260388)
Timeframe: 12 Weeks

InterventionT-Score (Mean)
Nortriptyline53.6
Duloxetine55.4
Pregabalin56.7
Mexiletine51.6

[back to top]

PROMIS Pain Interference Short Form v1.0 8a T Score

"Higher scores for pain interference represents worse outcome (more pain interference) T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population." (NCT02260388)
Timeframe: 12 weeks

InterventionT-Score (Mean)
Nortriptyline56.4
Duloxetine56.5
Pregabalin60.0
Mexiletine54.5

[back to top]

PROMIS Sleep Disturbance Short Form v1.0 8a

"Higher scores for sleep disturbance represents worse outcome (more sleep disturbance).~T-score metric: 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population.~On the T-score metric: A score of 40 is one SD lower than the mean of the reference population; A score of 60 is one SD higher than the mean of the reference population.~Higher scores equals more of the concept being measured" (NCT02260388)
Timeframe: 12 weeks

InterventionT-Score (Mean)
Nortriptyline58.9
Duloxetine58.9
Pregabalin58.3
Mexiletine59.1

[back to top]

Change in Placebo Corrected Change From Baseline QTc Interval on the ECG Measured in Milliseconds When Moxifloxacin is Administered With Diltiazem at the Evening Dose Compared to When Moxifloxacin is Administered Alone at Afternoon Dose on Treatment Day.

Evening dose (moxifloxacin+diltiazem) versus afternoon dose (diltiazem alone). (NCT02308748)
Timeframe: 5 weeks

Interventionms (Mean)
Moxifloxacin Alone29.9
Moxifloxacin + Diltiazem31.3

[back to top]

Change in Placebo Corrected Change From Baseline QTc and J-Tpeakc Intervals on the ECG Measured in Milliseconds When Dofetilide is Administered With Mexiletine or Lidocaine Compared to When Dofetilide is Administered Alone at Evening Dose on Treatment Day

After 3rd dose of mexiletine or lidocaine (evening dose) on treatment day when combined with dofetilide to evening dose on dofetilide alone day. (NCT02308748)
Timeframe: 5 weeks

,,
Interventionms (Mean)
Placebo corrected change from baseline in QTcPlacebo corrected change from baseline in J-Tpeakc
Dofetilide + Lidocaine183.5
Dofetilide + Mexiletine20.40.8
Dofetilide Alone37.924.0

[back to top]

Number of Participants With a Decrease in Cramp Duration

Participant will be evaluated for muscle cramps 120 minutes following a single dose of oral mexiletine. The Clinical Evaluator applied pressure to provoke hamstring cramps bilaterally, one at a time 2 hours after dose. The cramp duration in seconds of the right hamstring was used. (NCT02561702)
Timeframe: 120 minutes

Interventionparticipants (Number)
Mexiletine2
Placebo0

[back to top]

Number of Participants With a Decrease in Cramp Intensity

Participant will be evaluated for muscle cramps 120 minutes following a single dose of oral mexiletine. The Clinical Evaluator applied pressure to provoke hamstring cramps bilaterally, one at a time 2 hours after dose. The cramp intensity of the right hamstring was reported by the subject on a scale of 1-10 with 1 being weak and 10 being severe. (NCT02561702)
Timeframe: 120 minutes

Interventionparticipants (Number)
Mexiletine1
Placebo2

[back to top]

Effect on Frequency of Muscle Cramps

Will be assessed using a daily muscle cramps diary tabulated weekly beginning at Baseline. (NCT02781454)
Timeframe: Accessed at Screening, Baseline, Week 4, and Week 8; comparisons of treatments at Weeks 3-4 reported

Interventionmuscle cramps/week (Geometric Least Squares Mean)
Mexiletine, 300 Milligrams3.430
Mexiletine, 600 Milligrams1.987
Placebo3.774

[back to top]

Effect on Hyperpolarizing Threshold Electrotonus (90-100 ms)

Hyperpolarizing threshold electrotonus (90-100 ms) (TEh 90-100 ms) is used in threshold tracking nerve axonal excitability studies in which long-lasting subthreshold hyperpolarizing currents are generated, measured at 90-100 ms following the stimulus. This measure is associated with an increase in the membrane excitability threshold due to closure of potassium channels causing increased resistance of the internodal axonal membrane. Intrinsic changes in axonal excitability properties, such as thought to occur in ALS, could possibly alter this measure. (NCT02781454)
Timeframe: Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported

Interventionpercentage threshold hyperpolarization (Least Squares Mean)
Mexiletine, 300 Milligrams-10.184
Mexiletine, 600 Milligrams2.230
Placebo-4.219

[back to top]

Effect on Short-interval Intracortical Inhibition

Short-interval intracortical inhibition (SICI) is a measure of neuronal excitability measured by dual pulse TMS with a conditioned (80% of RMT) and test pulses (120% of RMT) to generate a stable MEP amplitude of 0.2 mV, averaged over interstimulus intervals of 1-7 ms. It is thought to reflect refractory cortical axons and subsequent resynchronization of cortico-cortical and corticomotoneuronal volleys or activation of non-GABAergic cortical inhibitory circuits (initial phase) and synaptic neurotransmission through GABAA receptors (second phase). The value for SICI thought to be maximally sensitive for detecting in changes in ALS subjects compared to controls is is derived by measuring the motor evoked potential amplitude (MEP) at an interstimulus interval of 3 ms (ISI 3 ms) and normalizing to the MEP amplitude at 120% of the resting motor threshold (MEP 120% RMT). A reduction in SICI reflecting greater excitability would generate a larger ratio of MEP ISI 3 ms/MEP 120% RMT. (NCT02781454)
Timeframe: Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported

Interventionunitless ratio MEP ISI 3 ms/MEP 120% RMT (Geometric Least Squares Mean)
Mexiletine, 300 Milligrams0.655
Mexiletine, 600 Milligrams0.886
Placebo0.961

[back to top]

Effect on Strength Duration Time Constant

The strength duration time constant (SDTC) is used in threshold tracking nerve axonal excitability studies and is interpreted as a measure of axonal excitability that is dependent upon the biophysical properties of the axonal membrane at the node of Ranvier, especially persistent sodium current. It is derived from the relationship between stimulus duration and intensity. A higher SDTC would reflect greater excitability of motor nerve axons. (NCT02781454)
Timeframe: Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported

Interventionmilliseconds (Geometric Least Squares Mean)
Mexiletine, 300 Milligrams0.895
Mexiletine, 600 Milligrams0.966
Placebo0.935

[back to top]

Effect on Subexcitability

Subexcitability is a component of recovery cycle analysis assessing motor axonal excitability, employing threshold tracking nerve conduction study. It is a late hyperpolarizing after potential measured following a single supramaximal stimulus followed by a second smaller stimulus of variable intensity and is related to the very slow turn-off of slow potassium channels. (NCT02781454)
Timeframe: Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported

Interventionpercentage of threshold change (Least Squares Mean)
Mexiletine, 300 Milligrams-2.563
Mexiletine, 600 Milligrams-0.575
Placebo0.448

[back to top]

Effect on Superexcitability

Superexcitability is a component of recovery cycle analysis assessing motor axonal excitability, employing threshold tracking nerve conduction study. It is a depolarizing afterpotential measured following a single supramaximal stimulus followed by a second smaller stimulus of variable intensity and reflects passive depolarization of the internodal axon. (NCT02781454)
Timeframe: Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported

Interventionpercentage of threshold change (Least Squares Mean)
Mexiletine, 300 Milligrams2.234
Mexiletine, 600 Milligrams1.511
Placebo-0.724

[back to top]

Change in Motor Evoked Potential Amplitude

The motor evoked potential (MEP) amplitude is taken from single pulse transcranial magnetic stimulation (TMS) and reflects the density of corticomotoneuronal projections onto motor neurons and is affected by cortical hyperexcitability early in ALS where it is thought to be larger than age-matched controls and axonal degeneration later in the disease when it decreases in amplitude. The MEP is most reliable in assessing cortical motor neuronal preservation and excitability when normalized to the peak compound nerve action potential (CMAP) amplitude which reflects the integrity of peripheral motor nerve axons. It is also normalized here to 120% of the RMT to derive a ratio of MEP at 120% RMT/peak CMAP. (NCT02781454)
Timeframe: Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported

Interventionunitless ratio of ms/ms (Geometric Least Squares Mean)
Mexiletine, 300 Milligrams0.589
Mexiletine, 600 Milligrams0.490
Placebo1.308

[back to top]

Change in Slow Vital Capacity

Measure of decline in respiratory muscle strength (NCT02781454)
Timeframe: Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported

Interventionmaximum percent predicted (Least Squares Mean)
Mexiletine, 300 Milligrams-0.532
Mexiletine, 600 Milligrams-6.918
Placebo-0.991

[back to top]

Change in the Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised

The Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised (ALSFRS-R) is an instrument for evaluating the functional status of patients with ALS that includes functions related to speech, swallowing, salivation, fine motor control, gross motor function, and respiration. The score is the sum of 12 items (range 0 to 48) with higher scores reflecting better function. (NCT02781454)
Timeframe: Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported

Interventionscore on a scale (Least Squares Mean)
Mexiletine, 300 Milligrams-1.414
Mexiletine, 600 Milligrams-1.038
Placebo-0.827

[back to top]

Effect on Cortical Silent Period

The cortical silent period (CSP) is recorded with single pulse TMS as a duration from the onset of the MEP response to resumption of voluntary electromyography activity with the patient performing a voluntary contraction, set to 30% of maximal voluntary contraction. A shorter CSP compared to controls would reflect greater excitability. (NCT02781454)
Timeframe: Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported

Interventionmilliseconds (Least Squares Mean)
Mexiletine, 300 Milligrams3.937
Mexiletine, 600 Milligrams4.823
Placebo4.037

[back to top]

Effect on Depolarizing Threshold Electrotonus (90-100 ms)

Depolarizing threshold electrotonus (90-100 ms) (TEd 90-100 ms) is used in threshold tracking nerve axonal excitability studies in which long-lasting subthreshold depolarizing currents are generated, measured at 90-100 ms following the stimulus. This measure is associated with a decrease in the membrane excitability threshold due to opening of potassium channels on the axonal membrane. Intrinsic changes in axonal excitability properties, such as thought to occur in ALS, could possibly alter this measure, presumably by decreasing TEd 90-100 ms more substantially than normal. (NCT02781454)
Timeframe: Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 reported

Interventionpercentage of threshold depolarization (Least Squares Mean)
Mexiletine, 300 Milligrams-0.140
Mexiletine, 600 Milligrams4.005
Placebo0.844

[back to top]

Effect on Frequency of Fasciculations (Muscle Twitching)

Will be assessed using a daily fasciculations diary tabulated as a percentage of days from weeks 3-4. (NCT02781454)
Timeframe: Accessed at Screening, Baseline, Week 4, and Week 8; comparisons of treatments at Weeks 3-4 reported

Interventionpercentage of days with fasciculations (Median)
Mexiletine, 300 Milligrams100
Mexiletine, 600 Milligrams100
Placebo100

[back to top]

Change in Resting Motor Threshold

The resting motor threshold (RMT) assessed from single pulse transcranial magnetic stimulation (TMS) measurements made before treatment, after 4 weeks of treatment, and then again after a 4 week washout, was used as the primary pharmacodynamic marker of cortical hyperexcitability. RMT is the stimulus intensity required to produce and maintain a 0.2 mV peak-to-peak motor evoked potential of the abductor pollicis brevis muscle by TMS. A smaller RMT is thought to suggest greater neuronal excitability. (NCT02781454)
Timeframe: Accessed at Screening, Baseline, Week 4, and Week 8; change from Baseline to Week 4 and from Week 4 to Week 8 reported

,,
Interventionpercentage of maximum stimulus output (Least Squares Mean)
change from baseline to week 4change from week 4 to week 8
Mexiletine, 300 Milligrams-2.4301.465
Mexiletine, 600 Milligrams0.805-0.284
Placebo4.746-2.908

[back to top]